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9ABSTRACT
Methicillin-resistant Staphylococcus
aureus (MRSA) is a major cause of
nosocomial infections worldwide, and
hospital outbreaks caused by MRSA
are common. Unless outbreaks are
controlled, MRSA may reside perma-
nently in a hospital environment. Such
endemic MRSA are difficult to eradi-
cate, and they most likely further in-
crease the number of infections, the
costs, and the length of hospital stays.
MRSA strains are commmonly resis-
tant to multiple antimicrobials, which
narrows treatment possibilities and
changes the spectrum of antibiotics
prescribed in hospitals.
This study was performed to
analyze comprehensively the Finnish
MRSA isolates collected through a
nationwide surveillance program since
1992 by various molecular methods.
We describe the elaboration of a typ-
ing scheme suitable for continuous
national surveillance in a country with
a low prevalence of MRSA, and ana-
lyze the overall trends of MRSA, as
well as the proportion of community-
acquired MRSA. We especially focus
on the characterization of predominant
MRSA strains linked to interhospital
epidemics and local intrahospital out-
breaks. We assess clonality, evolution,
association with community acquisi-
tion, and molecular traits linked to in-
creased transmissibility.
The baseline number of annual
MRSA remained stable in the 1980s
and early 1990s. After a peak caused
by extensive hospital epidemics in
1994, an increasing trend has been
observed. The incidence of MRSA in-
creased from 1.7 in 1995 to 5.0 in 2000
per population of 100,000. Between
1997 and 1999, one fifth of all MRSA
isolates were from persons who had
not been hospitalized within two years
before the date of the MRSA isolation.
It was suspected that these isolates had
been acquired in a community setting.
A total of 38 epidemic or local
outbreak strains were identified be-
tween 1992 and 2001. By phage typ-
ing, ribotyping, pulsed field gel elec-
tophoresis, and multilocus sequence
typing, 31 of these strains clustered
into eight different clones. Represen-
tatives of six clones had multilocus
sequence types identical to interna-
tional MRSA clones, the Brazilian,
Iberian, UK EMRSA-16, UK EMR-
SA-15, New York, and Berlin clones.
Together, these clones accounted for
35% of all MRSA isolates in 1997-
1999. The remaining two clones,
named Joensuu and Mikkeli, showed
a molecular epidemiology different
from that of the pandemic MRSA
clones. The multilocus sequence type
of Joensuu is commonly found among
international methicillin sensitive S.
aureus strains, and the Mikkeli se-
quence type is a single locus variant
of another, apparently rare, MRSA
type. The Mikkeli clone was the most
prevalent MRSA clone in Finland be-
tween 1997 and 2001.
Phage typing, ribotyping, and
pulsed field gel electrophoresis re-
vealed that three strains were associ-
ated with community acquisition.
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These strains belonged to the Mikkeli
and Joensuu clones, and the third was
a triple allele multilocus sequence
variant of the Joensuu clone.
Search for epidemicity markers
revealed two different populations of
MRSA strains. One group contained
strains showing mec hypervariable re-
gion hybridization pattern A combined
with a variety of ribotypes and resis-
tance to beta lactam antibiotics only.
The majority of these strains were spo-
radic by nature. The other group con-
tained strains with mec hypervariable
region hybridization pattern B or C in
association with two ribotypes, and
resistance to other antibiotic groups in
addition to beta lactams. This group
contained both epidemic and sporad-
ic strains.
Taken together, these results
suggest that two epidemiologically
and evolutionarily distinct MRSA
populations exist in Finland: 1) glo-
bal clonally disseminated, often mul-
tiresistant strains, and 2) strains sen-
sitive to multiple antibiotics with ge-
netic backgrounds related to methicil-
lin-sensitive S. aureus strains. Some
strains of the latter population may
have recently acquired the mec DNA
through horizontal transfer, and this
may have occured in a community
setting as well.
11
1. INTRODUCTION
Nosocomial infections cause a sub-
stantial burden for health and econom-
ics worldwide. A nosocomial infection
is defined as an infection acquired in
hospital, and which is not in the incu-
bation phase on the patient’s admis-
sion to hospital. However, a nosoco-
mial infection may be caused by a col-
onizing organism which the patient
carried before hospital admission (84).
Such endogenous, sporadic infections
account for the majority of all noso-
comial infections (136, 290, 302).
Cross-transmission may lead to epi-
demics, i.e. an increased number of in-
fections and/or colonizations.
Any microbial group, bacteria,
viruses, fungi, or parasites can cause
a nosocomial infection, but bacteria
are the most prevalent organisms.
Among gram positive bacteria, com-
mon nosocomial agents include sta-
phylococci, enterococci, streptococci,
and Clostridium difficile, and among
gram negatives, Escherichia coli,
Klebsiella sp, Enterobacter, Proteus,
Serratia, Pseudomonas aeruginosa,
Stenotrophomonas maltophilia, Acine-
tobacter spp, and Haemophilus spp.
An additional concern is the emer-
gence and dissemination of nosocomi-
al organisms with increased resistance
to antimicrobial agents. Such microbes
include methicillin-resistant S. epider-
midis and S. aureus, vancomycin-re-
sistant enterococci, multiresistant and
extended-spectrum beta-lactamase-
producing gram negative bacteria.
By extrapolating studies
performed in Sweden, Norway, and
the USA, it has been estimated that ap-
proximately 50,000 nosocomial infec-
tions occur annually in Finland, and
about 1000 persons without a serious
underlying disease die of nosocomial
infections (2, 17, 99, 155). A recent
study showed that the overall rate of
nosocomial bloodstream infections in
Finland is similar to the rates in En-
gland and in the USA, but S. aureus,
enterococci and fungi are less common
as causative agents in Finland (69,
157). The most common bloodstream
pathogens in Finland are coagulase
negative staphylococci (31%), Escher-
ichia coli (11%), and S. aureus (11%).
Comparison of the number of noso-
comial infections between hospitals
and countries is difficult for several
reasons. First, although definitions of
different types of nosocomial infec-
tions exist, they may be interpreted in
different ways by individual reseach-
ers. Second, comprehensive reporting
of nosocomial infections may be dif-
ficult to achieve without a substantial
resource input. Third, denominator
data should be suitable, and gathered
in a uniform way (30, 155)
Because of inevitable risk fac-
tors related to treatment or to patients,
nosocomial infections cannot be total-
ly eradicated. Invasive operations and
devices create opportunities for mi-
crobes to invade the host tissue, and
ingreasingly ill and compromised pa-
tients can be treated by evolving tech-
niques and equipment. Risk factors
most likely to result in colonization or
infection with multiresistant species
include advanced age, severity of ill-
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ness, inter-institutional transfer, pro-
longed hospital stay, gastrointestinal
surgery, transplantation, exposure to
medical devices, and exposure to
broad-spectrum antibiotics (236).
However, some of nosocomial infec-
tions are avoidable, namely those aris-
en through cross-transmission.
One of the most important
pathogens causing considerable mor-
bidity and mortality in hospitals is
methicillin-resistant S. aureus
(MRSA). Owing to expression of an
additional penicillin binding protein,
PBP2a, with decreased affinity to beta-
lactam agents, MRSA is resistant to
all beta-lactam antibiotics, including
cephalosporins and staphylococcal
penicillins (15). Many isolates of
MRSA are also resistant to several
other antimicrobial groups. Between
1997 and 1998, the SENTRY antimi-
crobial surveillance program gathered
a total of 3981 monthly consequtive
bacterial specimens from several types
of infections: bloodstream, pneumo-
nia, respiratory tract, skin and soft tis-
sue, and urinary tract infections. Twen-
ty-five European intensive care units
were involved. The most prominent
organism was S. aureus, and 39% of
the isolates were resistant to methicil-
lin (76).
The epidemiology of MRSA is
changing constantly. Two new stages
of MRSA evolution have occurred
during recent years: emergence of
MRSA strains with reduced suscepti-
bility or with resistance to glycopep-
tide antibiotics (GISA or GRSA
strains, respectively) (31), and com-
munity-acquisition of MRSA by per-
sons without known risk factors (29).
The first GISA strain was re-
ported in 1997 in Japan, and thus far
about two dozen strains of this type
have been reported in different parts
of world. The resistance mechanism
involves thickening of cell wall pep-
tidoglycan, which walls off vancomy-
cin from the target (110). In July 2002,
the first GRSA was reported in the
USA in a catheter exit site in a patient
with several underlying diseases and
multiple courses of antimicrobial ther-
apy. This strain showed minimal in-
hibitory concentration (MIC) of van-
comycin and teicoplanin of >128 µg/
ml and 32 µg/ml, respectively, and
contained the enterococcal vanA gene
(31).
Community-acquired MRSA
have been isolated from persons with
risk factors for MRSA, such as intra-
venous drug use or previous hospital
stays. However, between 1997 and
1999, community-acquired MRSA
caused fatal infections in four children
without any known risk factors for
MRSA (29). Although it is not known
whether the community-acquired iso-
lates were originally hospital born, it
seems that transmission of MRSA
may occasionally occur in the com-
munity, and serious infections may
develop in previously healthy persons.
This study focuses on molecu-
lar epidemiology of MRSA in Finland
by analyzing, by various typing meth-
ods, the MRSA strain collection gath-
ered by nationwide MRSA
surveillance between 1992 and 2001.
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The resulting molecular information al-
lows the development of a hypothesis
on the evolution of different populations
of MRSA, and examined together with
epidemiological background informa-
tion, the characterization of strains as-
sociated with community acquisition.
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 2. REVIEW OF THE LITERA-
TURE
2.1 STAPHYLOCOCCUS
AUREUS
2.1.1 Laboratory diagnostics
S. aureus is a gram positive, catalase
positive aerobic or anaerobic coccus
showing hemolytic and large yellow
colonies. The laboratory diagnostics
is based on culture and biochemical
tests: typical morphology, positive
coagulase reaction, fermentation of
mannitol and trehalose, and produc-
tion of heat stabile nuclease (thermo-
nuclease). The ability of coagulase to
clot plasma is the most widely used
method for identification. A four–hour
tube coagulase test with reconsituted
plasma is definitive, and a slide test
for bound coagulase is a means of rap-
id screening for species identification
(130). Latex agglutination tests, such
as Slidex Staph Plus (Biomérieux,
France) and Staphaurex Plus (Murex
Biotech, England), consist of latex
particles coated with IgG (bound by
protein A), fibrinogen (bound by
clumping factor), and IgG for S. au-
reus specific antigens. The thermonu-
clease can be detected using a metach-
romatic agar diffusion procedure and
DNA toluidine blue agar (143).
2.1.2 Cell wall
The outermost layers of pathogens are
important in the infection process (6).
Most S. aureus isolates are covered by
a polysaccharide capsule. Capsular
polysaccharides can be classified into
eleven different serotypes. Beneath the
capsule S. aureus harbors a typical
gram positive cell wall (86). The gram
positive cell wall differs from that of
gram negative bacteria in two major
characteristics: a gram positive cell
wall has a thicker and highly
crosslinked peptidoglycan layer, and
it lacks the outer membrane (12, 18,
220, 287) (Figure 1).
The peptidoglycan consists of
glycan strands of N-acetylglu-
cosamine-N-acetylmuramic acid
(GlcNAc-MurNAc) disaccarides,
crosslinked by tetrapeptides consist-
ing of L-alanine, D-glutamine, L-
lysine, and D-alanine (86). In S. au-
reus, a pentaglysine inter-bridge links
the tetrapeptide units of adjacent gly-
can strands. S. aureus produces four
penicillin-binding proteins, PBP1-4,
involved in the cell wall peptidogly-
can assembly (141). The biological ac-
tivity of these native PBPs is similar
to that of serineproteases, and they act
as transpeptidases in the crosslinking
of the glycan chains (181, 299). PBP2
Figure 1. Schematic presentation of S.
aureus cell wall.
Teichoic 
acid 
Capsule
Membrane
Peptidoglycan
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is a bifunctional protein which, in ad-
dition to transpeptidase activity, also
acts as transglycosylase (91). PBPs
bind effectively to beta-lactam antibi-
otics, and in the presens of these
agents, the cell wall assembly is dis-
continued.
Another common feature in the
gram positive cell wall is teichoic acid,
a carbohydrate-phosphate polymer
covalently linked to MurNAc (12).
Teichoic acids bind divalent cations
and possess antigenic properties (146).
2.1.3 Genome
The genomic positions of various ge-
netic markers of S.aureus have been
localized by creating physical maps of
the genome. The development of S.
aureus chromosomal maps began
through definition of three linkage
groups consisting of nine auxotrophic
markers and a novobiocin resistance
marker on S. aureus NCTC 8325
(211). By inclusion of a large number
of additional markers, and the use of
pulsed field gel electrophoresis
(PFGE) and subsequent hybridization
with available probes, the physical
map of S. aureus NCTC 8325 contin-
ued to be more and more precise (116,
210, 295) (Figure 2). However, until
data from genome sequencing became
available, the mutual distances be-
tween genetic markers within each
PFGE fragment were unknown.
sak  
A
N
B 
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D 
K 
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O 
A = 674  
B = 361 
C = 324 
D = 262 
E = 257 
F = 208 
G = 175 
H = 135 
I = 117 
J = 80 
K = 76 
L = 44 
M = 36 
N = 10 
O = 10 
P = 9 
purA spa 
fnbA, fnbB 
coa 
recA 
femA, femB 
Figure 2. S.aureus NCTC 8325 physical map. Adapted from (205). SmaI restriction frag-
ments A-P, their sizes in kilobase pairs, and examples of identified genetic markers.
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Knowledge of bacterial struc-
tures and functions has increased and
will further increase owing to recent
advances in genome sequencing and
in other genome-wide analysis. To
date, genomes of seven S. aureus
strains have been elucidated or are
soon to be completed, COL, NCTC
8325, N315, Mu50, MW2, UK EMR-
SA-16, and MSSA 476, (http://
www.sanger.ac.uk/Projects/S_aureus,
http://www.tigr.org/tigr-scripts/
CMR2/CMRHomePage.spl, http://
www.genome.ou.edu/staph.html) (11,
139). Half of all predicted proteins of
strain N315 were similar to those of
Bacillus subtilis or Bacillus halodu-
rans, and these proteins mostly coded
for essential functions such as DNA
replication, protein synthesis, and car-
bohydrate metabolism. Nearly 40% of
all predicted proteins were similar to
as yet unknown proteins, or showed
no sequence similarity in global data-
bases. Furthermore, some of the open
reading frames (ORFs) were similar
to those of taxonomically distant or-
ganisms, but not all of them differed
in GC content or codon usage. How-
ever, the first sextant of the chromo-
some showed accumulation of ORFs
with unusual codon composition. It
has been suggested that this region
contains exogenous genes recently
acquired through lateral transfer (139).
2.1.4 Diseases
Staphylococcus aureus causes a wide
variety of diseases, from mild skin in-
fections to severe life threatening sys-
temic infections (297). It is a common
cause of skin and subcutaneus infec-
tions, including folliculitis, furuncu-
losis, cellulitis, mastitis, and impeti-
go. Recurrent abscesses of the skin and
the subcutaneous tissue may be diffi-
cult to treat. The preferable tratment
for folliculitis and local abscesses is
surgical drainage, whereas cellulitis is
usually treated with antimicrobials.
Impetigo can range from mild, recur-
rent infections to a more severe
bullous form and to the potentially
life-threatening scalded skin syndrome
(144). S. aureus is also commonly as-
sociated with postoperative wound in-
fections, catheter-related infections,
toxic shock syndrome (TSS), and food
poisoning. TSS and food poisoning are
toxin-mediated diseases. The com-
mon, self-limiting, food poisoning is
caused by enterotoxins present in con-
taminated food, and is characterized
by nausea, vomiting, headache, and
sometimes diarrhea. The symptoms
start four to five hours after consump-
tion of contaminated food (112, 304).
TSS, caused by TSST-1, is a poten-
tially fatal condition, most commonly
associated with the use of highly ab-
sorbent tampons, but also known in
non-invasive S. aureus infections in
children. The symptoms include high
fever, rash, desquamation of skin one
to two weeks after onset, hypotension,
and involvement of multiple organ
systems (63, 247, 268)
Serious S. aureus infections in-
clude osteomyelitis, pneumonia, sep-
sis, acute endocarditis, myocarditis,
pericarditis, cerebritis, meningitis,
scalded skin syndrome, and sterile site
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abscesses (297). S. aureus pneumonia
is rare in a community setting, but fair-
ly common in a hospital setting, espe-
cially as a consequence of influenza
in elderly patients (154). Acute osteo-
myelitis primarily affects long bones
in children, whereas chronic (duration
of infection >6 months) osteomyelitis
is more common in adults after bacte-
remia, or as a complication of pene-
trating wounds (298). S. aureus sep-
sis most often originates in a local in-
fection focus such as cellulitis, pneu-
monia, or a wound, or is related to an
intravascular device (301). Complicat-
ed sepsis may hematogenously spread
the infection to other organs, such as
heart, bone, and joints. Annually, S.
aureus causes 700-900 septic infec-
tions in Finland, and is the third most
common causative agent of nosoco-
mial sepsis (157). S. aureus endocardi-
tis can present as right-sided en-
docarditis, often among intravenous
drug users, as left-sided native valve
infection, or as prosthetic valve en-
docarditis (120)
2.1.5 Carriage
Nasal carriage of  S. aureus is one of
the major risk factors for S. aureus
infection (131). Although S. aureus
can be found in different parts of the
body, anterior nares is the primary eco-
logical niche in humans (65, 227). In
the healthy population 10-35% of in-
dividuals carry S. aureus persistently,
20-75% intermittently, and 5-50%
never carry S. aureus in the nose. Pro-
portions of nasal carriage patterns dif-
fer, depending on the study design and
definitions for persistant-, intermit-
tent-, and non-carrier (192). Other risk
factors for S. aureus infection include
age, dialysis, repeated rupture of the
skin, and underlying conditions, such
as renal or liver disease and diabetes.
2.1.6 Virulence factors
S. aureus harbors an extensive arse-
nal of virulence factors contributing
to its ability to propagate and spread
within the human host. The form and
severity of the disease result from a
complex interplay between the host
defense and the activities of the viru-
lence factor repetoire of the infecting
strain. Considerable knowledge exists
on the contribution of several viru-
lence factors to specific diseases.
Much less is known of the conserted
action of these factors, their interac-
tion with the host, and the relative im-
portance of each factor in infection.
One virulence factor may be indis-
pensable in some infections, but insig-
nificant in others. According to their
biological function, the virulence fac-
tors can be divided into three groups:
those involved in adhesion, in host
defense evasion, and in tissue pene-
tration (Table 1). One factor can serve
in one or more of these activities, and
different factors are produced in dif-
ferent growth phases.
Most clinical S. aureus strains
produce capsular polysaccaride of se-
rotype 5 or 8. The capsule may inhibit
binding of antibodies and thereby op-
sonization, and phagocytosis (264,
266). In addition, capsular polysaccha-
ride may have a role in bacterial ad-
18
↑ 
Table 1. Examples of Stapylococcus aureus virulence factors.  = upregulation,    = downregulation. Adapted from (223), table 3-1, and from (193),
table 1. n.d, not determined or not reported in the literature.
↑ 
Virulence factor Gene Regulation system Production
phase
Proposed virulence
function
Reference
Clumping factor clfA sar  Exponential Attachment (41, 175)
Fibrinogen binding protein A fbaA agr , sar Exponential Attachment (40)
Fibronecting binding protein B fnbB agr , sar Exponential Attachment, invasion (45, 127, 173,
252)
Collagen binding protein cna sar  Exponential Attachment (21)
Coagulase coa agr , sae Exponential Attachment (87, 226)
Protein A spa agr , sarA  ,
sarS  ,sae 
Exponential Host defence evasion,
attachment
(42, 87, 104)
Enterotoxin A entA agr All Host defence evasion (63)
Enterotoxins B-E, G-J entB-E, entG-J agr Postexponential Host defence evasion (63)
Toxic shoc syndrome toxin tst agr , sar Postexponential Host defence evasion (63)
Exfoliative toxin eta, etb agr Postexponential Host defence evasion (144)
Lipase geh agr , sar Postexponential Host defence evasion (21)
Serine protease spr agr , sar Postexponential Host defence evasion (224)
V8 protease sasP, sspA agr , sar Postexponential Host defence evasion (8, 127)
Fatty acid metabolizing
enzyme
n.d. agr , sar Postexponential Host defence evasion (33, 178)
Penton-Valentine leucosidin lukF-PV, lukS-
PV
n.d. Postexponential Host defence evasion
Leucosidin R lukF-R, lukS-R agr n.d. Host defence evasion
Capsular polysaccarides cap1-8 locus agr Postexponential Host defence evasion (156)
Staphylokinase sak agr n.d. Host defence evasion (8)
Hemolysins  ,  ,  hla, hlb, hld agr , sarA  Postexponential Tissue penetration (226)
Hemolysin  hlg agr Postexponential Tissue penetration (8)
Phospholipase C plc agr n.d. Tissue penetration (8)
Metalloprotease aur agr n.d. Tissue penetration (8)
Hyaluronidase hysA, hal agr Postexponential Tissue penetration (8)
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hesion to polymer surfaces in medi-
cal devices (180).
The role of free coagulase in the
virulence of S. aureus is uncertain.
However, since it is produced by the
majority of strains and has biological
function as a prothrombin activator, it
is considered a probable virulence fac-
tor. The cell wall bound clumping fac-
tor, another fibrinogen binding pro-
tein, shares a significant sequence sim-
ilarity with coagulase, and its role in
adherence is clearer than that of coag-
ulase (61, 175, 250).
Surface proteins needed in at-
tachment to host tissue are expressed
in the logarithmic growth phase dur-
ing cell wall synthesis. These micro-
bial surface components recognizing
adhesive matrix molecules
(MSCRAMMs) (212) include fi-
bronectin binding protein, fibrinogen
binding protein, collagen binding pro-
tein, and clumping factor. Protein A,
another surface protein also produced
during cell wall synthesis, may have
a role in host defense evasion, since
its biological function is to bind the
IgG Fc-domaine (277). The surface
proteins of gram positive bacteria have
a common overall structure. An ami-
noterminal secretory signal peptide di-
rects the export of the protein, and it
is then cleaved off. The hydrophobic
carboxyterminal remains within the
cell membrane, and just outside of the
cell membrane the protein is then
cleaved between threonine and glycine
residues in a well-conserved LPXTG
motive. In staphylococci, the protein
is anchored to the pentaglycine cross-
bridge in the cell wall peptidoglycan.
A proline-rich area spans the cell wall,
and the extracellular amino-terminus
contains a unique sequence that rec-
ognizes the target molecule in its en-
vironment (77).
S. aureus produces a wide vari-
ety of exoproteins, most of them dur-
ing the postexponential growth phase.
These proteins degrade the host tissue
to nutrients required for the growth of
the bacteria, and/or allow the bacteria
to penetrate deeper into the host tis-
sue (63). The majority of strains pro-
duce hemolysins, nucleases, proteas-
es, lipases, hyaluronidase, and colla-
genase. Alpha-hemolysin (or alpha-
toxin) is dermonecrotic, neurotoxic,
and lyses mammalian cells, especial-
ly red blood cells, by forming a pore
in the target membrane (19). Beta-
hemolysin acts as sphingomyelinase,
gamma-hemolysin has leucocytolytic
activity, and it has been suggested that
delta-hemolysin has surfactant or
channel forming properties (63). Sta-
phylokinase is a plasminogen activa-
tor (145). Hyaluronidase digests hy-
aluronic acid present in the skin, bone,
umbilical cord, vitreous body of the
eye, and synovial fluid. Some S. au-
reus strains produce additional exo-
proteins, which may have host defense
evasion as their major function in vivo.
One serine protease has the ability to
cleave and inactivate IgG antibodies
(224). Another function of proteases
may include protection against anti-
microbial peptides. It has been pro-
posed that a fatty acid modifying en-
zyme (FAME) detoxifies bactericidal
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fatty acids (178). Penton-Valentine
leucocidin (PVL) has leucocytolytic
activity. Exfoliative toxin, TSST 1,
and enterotoxins A-E and G-J are po-
tent superantigens (63, 144).
Genes for S. aureus virulence
factors may reside in plasmids, bacte-
riophages, transposons, or pathogenic-
ity islands of the chromosome. Recent
sequencing of two S. aureus strains
revealed three new classes of patho-
genicity islands: TSST family islands,
exotoxin islands, and enterotoxin is-
lands. A considerable number of new
putative virulence genes were also
identified (139).
The genes coding for virulence
factors are not essential for cell-divi-
sion and growth, but are useful in cer-
tain situations and environments. Con-
stitutive expression of these genes
would be an unnecessary waste of en-
ergy. Instead, many virulence factors
are concomitantly upregulated, where-
as others, not needed at that point in
time, are down-regulated (Table 1).
Two major global regulator systems
have been identified: accessory gene
regulator (agr) and staphylococcal ac-
cessory gene regulator (sar) (8). Oth-
er regulatory genes and operons, such
as sae, sigB, ssrA-ssrB, and arlS-srlR
(78, 87, 138, 310), as well as environ-
mental factors (172), also affect the
regulation of virulence factors.
The agr regulation turns off the
surface protein expression in the late
exponential phase of growth, and turns
on the synthesis of secreted proteins
for a relatively short time period. The
swich-off mechanism of the secreted
proteins’ expression is unknown. Two
distinct agr gene products, generated
from promoter P2, form a classical sig-
nal transduction pathway, which is
activated by an autoinduction protein
also translated from the same promot-
er. Signal transduction leads to acti-
vation of a response regulator AgrA
(195). AgrA acts together with anoth-
er accessory transcription factor, SarA,
to further upregulate promoter P2 and
another agr promotor, P3 (43). The
transcript from the latter, RNAIII, is
the actual effector in the agr-regula-
tion (195). RNAIII primarily acts at
the transcription level, probably
through one or more regulatory pro-
teins. It has also been shown that
RNAIII forms a specific complex with
leader sequences of some of the up-
regulated genes (177). SarA, coded for
by the sar locus, regulates the expres-
sion of certain exoprotein genes direct-
ly, without agr-activity. Many such
genes, as well as the intergenic region
between P2 and P3 of the agr operon,
contain an AT-rich sequence recog-
nized by SarA (43).
2.1.7 Pathogenesis
Staphylococcal pathogenesis results
from various bacterial activities me-
diated by virulence factors, and from
the immunological response by the
host. It is commonly thought that bac-
terial adherence to host tissue is a pre-
requisite for colonization and infec-
tion. This is achieved by the
MSCRAMMs (212). Subsequent sur-
vival, growth, and establishment of
infection depend on the ability of the
bacterium to circumvent host defense.
The primary host response is mediat-
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ed by polymorphonuclear leucocytes
(288), which are attracted by expres-
sion of adhesion molecules on endot-
helial cells. The cell wall components,
peptidoglycan and teichoic acids, trig-
ger signaling pathways leading to the
release of cytokines (70, 106). Leu-
cocytes and other host cellular factors
can be destructed by locally acting
bacterial toxins. Anti-inflammatory
response is also achieved by the sta-
phylococcal extracellular adherence
protein, Eap, which inhibits the re-
cruitment of host leucocytes by direct
interaction with the host adhesive pro-
teins ICAM-1, fibrinogen, and vit-
ronectin (39). If not attenuated
enough, however, the robust local in-
flammatory response may lead to the
formation of an abscess. Inside an ab-
scess, the bacteria gradually fall into
a state of nutritional stress as the den-
sity of bacteria increases. At this point
the autoinduction of secreted virulence
factors could enable the bacteria to
break out and spread to new locations
(194).
In toxin mediated diseases, su-
perantigens bind non-specifically to
the major histocompatibility complex
II (MHC II) and crosslink it to the vari-
able beta chain of T-lymphocyte.
Since the normal route of internaliza-
tion, processing, and antigen presen-
tation is bypassed, this unspecific
binding leads to massive expansion of
T-lymphocytes and production of cy-
tokines. Superantigens also induce
endotoxin hypersensitivity and bind
directly to endothelial surfaces, prob-
ably causing capillary leakage through
endothelial cell death or intercellular
gap formation.
In invasive diseases, such as
sepsis and endocarditis, staphylococ-
ci must interact with the endothelium.
By using MSCRAMMs, the bacteria
can adhere to damaged areas of the en-
dothelium, or directly to the endothe-
lial cell via the adhesin-receptor mech-
anism or via bridging ligands (122).
The bacteria may then be phagocy-
tized into endothelial cells (102, 196)
and/or reach the underlining tissue
(154). Both endothelial phagocytosis
and tissue invasion elicit an inflam-
matory response leading to the relase
of IL -1, -6, -8, tumor necrosis factor
(TNF), and subsequently interferon-
gamma. Leucocytes adhere to endot-
helial cells and increase vascular per-
meability.
Although S. aureus is primarily
an extracellular pathogen, it may
sometimes survive inside non-profes-
sional phagocytes, such as fibroblasts,
renal cells, and osteoblasts. Intracel-
lular survival may explain the persis-
tent and recurrent nature of certain sta-
phylococcal infections (222). Intrac-
ellular staphylococci often appear as
small colony variants which have
mutations affecting electron transport
(170), and show slowly growing, non-
pigmented colonies with reduced pro-
duction of virulence factors (291).
2.2 METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS
2.2.1 Methicillin resistance
Methicillin-resistant strains of S. au-
reus are able to grow in the presence
of beta-lactams and its derivatives,
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including cephalosporins and staphy-
lococcal penicillins. Low-level methi-
cillin resistance can result from the
production of large amounts of beta-
lactamases, or increased production
and/or modified penicillin-binding ca-
pacity of normal PBPs (168, 269).
Such borderline resistant S. aureus
strains (BORSA) seldom have mini-
mal inhibitory concentrations (MIC)
of methicillin exceeding 16 µg/ml, and
their clinical significance is thought to
be limited. The challence is to differ-
entiate BORSA strains from the true
methicillin-resistant Staphylococcus
aureus (MRSA) strains (35).
The most clinically relevant and
the most prevalent form of methicil-
lin resistance is characterized by pro-
duction of an additional penicillin
binding protein, PBP2a (or PBP2’)
(26, 228, 275). PBP2a has probably
evolved by recombination of a peni-
cillinase gene and a PBP gene similar
to PBP2 and PBP3 of Escherichia coli
(255). PBP2a has an unusually low
binding affinity for all beta-lactam
antibiotics, substituting the native
PBPs and allowing continuous cell
wall assembly (36, 228). However, the
production of  PBP2a alone is not suf-
ficient for optimal expression of me-
thicillin resistance (216). Native PBP2
provides the transglycosylase function
of glycan chain elongation in spite of
the presence of beta-lactams, and
PBP2a is required for the transpepti-
dase function (215).
The PBP2a is inducible and cod-
ed by the mecA gene, which is part of
an additional DNA region, staphylo-
coccal casette chromosome mec (SC-
Cmec), found in methicillin-resistant
strains, but not in methicillin-suscep-
tible strains (14, 128, 167). SCCmec
is always located in the same region
in the S. aureus chromosome, between
spa and purA (137, 209). The se-
quence of the chromosomal region
where SCCmec is integrated seems to
be highly homologous among differ-
ent strains. Four structurally different
SCCmec types (SCCmec I-IV) and a
few variants have been identified (Fig-
ure 3.) (117, 158, 198). All SCCmec
types contain common features, in-
cluding the mecA gene and part of its
regulatory region, and ccrA and ccrB
genes.  The mecR1- and mecI-genes
code for the regulatory proteins of the
mecA, MecR1 is a signal transducing
protein with a penicillin binding do-
main and a transmembrane domain,
and MecI is a repressor protein of the
mecA gene (140, 248, 263). ccrA and
ccrB code for recombinases CcrA and
CcrB of the resolvase-invertase fami-
ly. CcrA and CcrB are required for site
and orientation specific integration
and excision of the SCCmec (118,
128).
Other genetic and environmen-
tal factors independent of SCCmec
also have influence on methicillin re-
sistance (15, 16, 34, 56, 57, 235). In-
sertional inactivation studies have
identified several normal staphylococ-
cal genes necessary for methicillin re-
sistance. Mutations in these fem (fac-
tors essential for methicillin resis-
tance) or aux (auxilliary) factors in-
hibit the peptodoglycan precursor for-
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mation (Figure 4). FemA, FemB, and
FemX (or FmhB) add glycine recid-
ues in the pentaglycine interbridge
between peptidoglycan strains (230,
256). Amidation of glutamate in the
stem peptide is inhibited in femC (or
glnR) mutants (97, 257), glucosamine-
1-phosphate formation is inhibited in
femD (or femR or glmM) mutants
(124), and precursor formation is
blocked at the lysine addition step in
femF mutants (202). Other factors that
may have influence on methicillin re-
sistance include global regulators sar
and agr (217), ilm gene coding for a
lipophilic membrane protein, and
genes coding for murein hydrolases.
The expression of methicillin re-
sistance varies among strains (107,
166, 234). Strains with intact mecI-
mecR1 regulon are phenotypically
methicillin sensitive, since mecA is ef-
fectively repressed by MecI (260).
Constitutive expression of methicillin
Figure 3. SCCmec types according to published sequences, accession numbers AB033763
(SCCmec I), AB063172 (SCCmec IV), D86934 (SCCmec II), and AB037671 (SCCmec III).
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SCCmecIII, 67kbp
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resistance requires alterations in reg-
ulatory genes and absence of beta-lac-
tamase regulatory genes (blaI and
blaR1), which are also able to repress
mecA (98). Clinical MRSA isolates
show deletions in mecI and some
mecR1 regions, or mutations in mecI
or in the promoter region of mecA
(133, 260). Some strains express me-
thicillin resistance heterogeneously;
only a small subset of the population
(10-3-10-7) is resistant to high methi-
cillin concentrations. Others are ho-
mogeneously resistant, i.e. each bac-
terium of the population shows uni-
form high-level resistance (107).
Strains with eagle-type resistance are
sensitive in low concentrations of
methicillin, but resistant in high con-
centrations. This type of resistance is
achieved by exposing strains with in-
tact mecA regulon to a high methicil-
lin concentration. The expression of
eagle-type resistance and the conver-
sion of heterogeneous resistance to
homogeneous resistance are thought
to result from the same genetic factor
independent of SCCmec and fem fac-
tors (134, 234).
Methicillin-resistant strains of S.
aureus are often resistant to other an-
tibiotic groups in addition to beta lac-
tams. The SCCmec itself may carry
several resistance genes generally lo-
cated in integrated plasmids or trans-
posons. Macrolide-lincosamine-strep-
togramin (MLS) resistance resides
within Tn554, and has been linked to
SCCmec types II, III, and IIIA (44,
265). Tetracycline resistance gene lies
in pT181 in SCCmec type III (129).
Aminoglygoside resistance genes are
located either within pUB110 (aadD,
tobramycin resistance) (28) found in
SCCmec types IA and II or in pG01
(gentamycin resistance), which also
Figure 4. Factors affecting peptidoglycan assembly and methicillin resistance.
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L-Ala
L-Glu
L-Lys
D-Ala
D-Ala
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contains a gene for trimetoprim resis-
tance (179). Fluoroquinolone resis-
tance often forms during treatment
because of mutation in the topoi-
somerase IV gene (grlA), the primary
target of these agents in staphylococ-
ci, and high-level resistance arises
through an additional mutation in the
DNA gyrase gene (126, 189). Rifamp-
in and mupirocin resistance occur be-
cause of a point mutation in target en-
zymes, RNA polymerase and isole-
ucyl-t-RNA synthethases, respective-
ly (9, 300). High-level resistance to
mupirocin arises through acquisition
of a plasmid containing an additional
isoleucyl-t-RNA-synthethase gene
(276), but other mechanisms may also
be involved (241). Strains intermedi-
ately resistant to glycopeptides
(GISA) have been described in differ-
ent geographic locations (110, 162,
219, 232, 253). The molecular mech-
anism of resistance has not been fully
elucidated. However, thickening of the
cell wall through accumulation of ex-
cess peptidoglycan, either by in-
creased synthesis or by decreased turn-
over, seems to be common to all GISA
strains (52, 103, 108). This results in
the trapping of glycopeptide mole-
cules in the cell wall, and the block-
ing of the access to the major target of
glycopeptide antibiotics, D-ala-D-ala
residue on the N-acetyl-muramicacid
precursor in the cytoplasm (108). Re-
cently, a truly glycopeptide resistant
strain (GRSA) was isolated. This
strain had the vanA gene of glycopep-
tide resistant enterococci. A vancomy-
cin-resistant enterococcus was also
isolated from the same infection site,
suggesting that a van gene transfer
from enterococci to staphylococci may
have occurred (31).
Primary diagnosis of methicil-
lin resistance can be performed
through antimicrobial susceptibility
testing recommended by National
Committee for Clinical Laboratory
Standards (NCCLS). The test methods
are based either on diffusion of oxacil-
lin from commercially prepared filter
paper disks into the agar or on serial
twofold dilution of oxacillin in an agar
or broth base (187, 188). A commer-
cially available MIC test, E-test (AB
Biodisk, Sweden), is widely used in
Finland. Heterogeneously resistant
MRSA strains grow more slowly than
do homogeneously resistant strains,
and may be more difficult to detect.
Addition of NaCl to the growth medi-
um, an incubation temperature of
30 °C, and an incubation time of 48 h
aid detection. Automated antimicro-
bial susceptibility testing systems are
widely used in the USA, but not in Fin-
land. A commercial agglutination test
(MRSA Screen, Denka Seiken, Japan)
based on the detection of PBP2a, and
commercial agar plates with oxacillin
supplements, are available for the
screening for methicillin resistance
(132). Definitive diagnosis is achieved
using the detection of the mecA gene
by PCR (182), hybridization, or a com-
mercially available fluorescence test.
2.2.2 Evolution of MRSA
First MRSA strains were described in
1961 (121), in the same time period
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when methicillin was introduced into
clinical use. The origin of the mecA
gene and SCCmec is unknown, but the
mecA gene and the flanking regions
have also been detected in other sta-
phylococcal species. One possible
source is Staphylococcus sciuri, since
one series of studies suggested that
mecA is a native element in S. sciuri;
a mecA gene, showing 88% overall
similarity with mecA of MRSA, was
present in each of more than 100 in-
dependent isolates from different eco-
logical sources and representing a
wide variety of genotypes (49). How-
ever, the majority of these isolates
showed no resistance to methicillin.
The isolates which were resistant to
methicillin had a further copy of mecA,
identical to that of MRSA isolates (46,
309).
The mode of transfer of the
mecA gene from an unknown donor
to S. aureus has been subject to a de-
bate. Initially, all MRSA strains were
thought to be descendants of a single
common ancestor, since they showed
pigmentation different from MSSA
strains, invariable survival capacity,
and a typical resistance profile (142).
Later, their clonality was studied in a
more precise way by using a MRSA
strain collection of 472 isolates from
different geographic areas, and DNA
probes to the mecA region and staphy-
lococcal transposon Tn554. Twenty-
nine Tn554 patterns and six different
temporally ordered mecA patterns
were found. Each Tn554 pattern as-
sociated with only one mecA pattern,
suggesting that Tn554 polymorphism
had arisen after mecA integration into
the S.aureus chromosome (135). How-
ever, another study suggested that
mecA had integrated into different S.
aureus lineages as evidenced by size
differences in the evolutionary well-
conserved housekeeping proteins
(183). The same protein profiles were
also found in common MSSA strains.
When a set of MRSA strains with
these protein profiles were recently an-
alyzed using microarrays comprising
96% of the S.aureus COL genome, it
became evident that SCCmec had in-
tegrated into at least five MRSA lin-
eages, which were highly different in
their overall gene content (75). It
seems, however, that the horizontal
transfer of SCCmec is a relatively rare
event, although horizontal transfer of
genetic material othervise plays a ma-
jor role in the evolution of S. aureus
(75, 139)
2.2.3 MRSA surveillance
The trends of MRSA numbers and the
characteristics of isolates (e.g. antimi-
crobial resistance) can be followed by
surveillance systems (13). The surveil-
lance may be ongoing, restricted to
certain defined areas (e.g. high risk
units or operations) and performed at
several levels (local, national, interna-
tional), and should always include
feedback information to the instances
which provided the data. The surveil-
lance aims at recognizing outbreaks,
monitoring the success of infection
control methods, and ultimately reduc-
ing the number of MRSA and costs
attributable to MRSA infections. In-
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dividual hospitals often report the to-
tal number of MRSA strains isolated
within a certain time period. Compari-
son of these reports may be difficult
owing to differences or lack of denom-
inator data. National MRSA data may
be gathered as part of nosocomial in-
fections surveillance systems, and
some countries additionally require
MRSA cases to be reported to nation-
al infectious diseases registers (http://
www.ktl.fi/ttr/). The Nosocomial In-
fection National Surveillance Scheme
(NINSS) in the UK involves monitor-
ing blood stream infections and surgi-
cal site infections of more than 100
hospitals (http://www.phls.co.uk/ser-
vices/nisu.htm). The National Noso-
comial Infections Surveillance (NNIS)
System in the USA is based on volun-
tary participation of 315 acute-care
general hospitals (http://
www.cdc.gov/ncidod/hip/surveill/
nnis.htm). International initiatives in-
clude HELICS (Hospitals in Europe
Link for Infection Control through
Surveillance), one of whose tasks is
to define and validate a methodology
for pooling and analyzing nosocomi-
al infection data from intensive care
and surgery units, collected in Euro-
pean networks (http://helics.univ-
lyon1.fr/index.htm). EARSS (Europe-
an Antibiotic Resistance Surveillance
System) collects antimicrobial resis-
tance data in a standardized manner,
allowing analysis of temporal and geo-
graphical resistance trends (http://
www.ears.rivm.nl) (90). The SEN-
TRY Antimicrobial Surveillance Pro-
gram monitors the predominant patho-
gens and antimicrobial resistance of
nosocomial and community-acquired
infections through global sentinel hos-
pitals. The objects covered by SEN-
TRY include bacteremia, fungemia,
outpatient respiratory infections,
wound infections, and urinary infec-
tions (62).
2.2.4 MRSA in health care facili-
ties
S. aureus is one of the major causative
agents of nosocomial bacteremia (69),
postoperative wound infection (190,
213), and catheter related infections
(71). Most nosocomial S. aureus in-
fections are endogenous, caused by the
patient’s own carriage strain (136).
Susceptibility information on S. au-
reus bacteremias, gathered by the
EARSS, indicate that the proportion
of methicillin resistant strains in Eu-
rope varies from country to country,
and reaches 40-50% in several areas
(Figure 5). The Nordic countries and
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Figure 5. Proportion (%) of S. aureus resis-
tant to methicillin in European countries in
1999-2001. Den, Denmark; Ger, Germany;
Bel, Belgium; UK, United Kingdom; Ita, Italy.
Source: EARSS (http://www.earss.rivm.nl/
index.html).
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the Netherlands still have low propor-
tions of MRSA in S. aureus bactere-
mias, from 0 to 2.5% in 1999 through
2001 (http://www.earss.rivm.nl/
index.html). A recent study revealed
that the proportion of MRSA among
S. aureus blood isolates rose from 18.1
to 26.1% in San Francisco County be-
tween 1996 and 1999 (113). The US
National Nosocomial Infections Sur-
veillance System (NNIS) reported a
55.3% methicillin resistance rate
among S. aureus strains from 5070
ICU patients in 2000, indicating an
increase of 29% compared with the
previous five years (1), (http://
www.cdc.gov).
Prevalence studies show that
MRSA is a major cause of nosocomi-
al infections worldwide, and may ac-
count for up to 20-40% of all S. au-
reus infections (258, 293). In the USA,
the prevalence of MRSA in hospitals
increased from 2.4% in 1975 to 29%
in 1991 (205). Similar trends have
been reported in Europe. In central
Europe, the prevalence of MRSA in-
creased from 1.7% in 1990 to 8.7% in
1995 (307). In Australia, MRSA has
attained endemic levels of 20-40% in
the eastern cities, Sydney, Melbourne,
and Brisbane, during the past decade.
Other major Australian cities, Perth,
Darwin, Adelaide, and Camberra, had
lower rates of MRSA in the beginning
of the 1990s. Recently, proportions of
MRSA in these latter cities have been
approaching to those of Sydney (272).
Data on MRSA prevalence in Asia and
Africa are scarce, but sporadic reports
suggest a rapid increase of methicil-
lin resistance among S. aureus: from
2% in 1988 to 33% in 1998 in two
Saudi-Arabian tertiary-care hospitals
(159), from 26.7% in 1990 to 70.9%
in 1997 in one hospital in Taiwan (37),
and from 9.8% in 1992 to 45.4% in
1998 in India, according to a surveil-
lance study on S. aureus strains sub-
mitted for typing (171). Prevalence
studies of short time periods revealed
27.5% and 30.5% methicillin resis-
tance among S. aureus isolates in Sri
Lanka and Ethiopia, respectively (85,
267)
The proportion of methicillin
resistance of S.aureus varies among
hospitals of individual countries. This
variation has previously been corre-
lated with the number of hospital ICU
beds, total beds, annual admissions, or
annual length of stay (100, 119, 205).
Recently, this correlation has become
less evident (113). Extensive use of
antibiotics within a hospital may partly
explain differences among hospitals in
transmission rates of resistant organ-
isms (249).
 The main reservoir of MRSA
in hospitals consists of infected or col-
onized patients. The spread of MRSA
from one patient to another occurs
mainly through contaminated hands of
health care personnel (254). The
MRSA prevention methods in non-en-
demic countries, such as Finland, in-
clude careful hand desinfection after
each patient contact, wearing gloves
and a gown when caring for MRSA
patients, treatment of colonized pa-
tients, and isolation of MRSA patients
and suspected MRSA positive patients
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until three negative MRSA cultures
have been obtained. (289, 294). In Fin-
land, a patient is suspected to be a
MRSA carrier if the patient has previ-
ously been MRSA positive, has shared
a room with a MRSA positive patient,
has been hospitalized outside the Nor-
dic countries within the past six
months, or has been transferred from
a hospital with an ongoing MRSA ep-
idemic (294). Countries with endem-
ic MRSA focus their screening and
isolation resources on high risk depart-
ments where the impact of MRSA
spread is most pronounced  (67).
The primary route of nosocomi-
al MRSA spread between hospitals
and countries is clonal dissemination
of relatively few international epidem-
ic clones. In the UK, the first epidem-
ic MRSA (UK EMRSA-1) seemed to
be similar to the epidemic strain in
eastern Australia (270). This strain
was later superceded by a series of
other MRSA strains (UK EMRSA-2-
14), and in the 1990s by UK EMR-
SA-15 and –16 (163, 174). UK EMR-
SA-15 and-16 gradually spread
throughout the country, and they have
also been identified elsewhere in Eu-
rope. In Germany, six different epi-
demic strains have gradually dissemi-
nated throughout the country (306).
The Iberian and Pediatric clones, orig-
inally identified in Spain and Portu-
gal, respectively, have subsequently
been identified in several countries in
Europe, Latin America, and in the
USA (58, 93, 165, 229). The New
York strain has spread widely in the
USA and a similar strain also exists
in Japan (7). Why these particular
clones have been so successful in
spreading remains to be elucidated.
2.2.5 Community-acquired
MRSA
MRSA strains of nosocomial origin
may be transmitted in the community
through discharged patients or health
care workers. Another possibility is
that MRSA strains arise de novo
through acquisition of SCCmec into
the genomes of previously suscepti-
ble S.aureus strains.
Long-term care facilities, such
as nursing homes, have been suspect-
ed as being reservoirs of MRSA. Re-
cent studies suggest that, in the USA,
long-term care residents commonly
harbor antibiotic-resistant organisms,
and MRSA is the most common or-
ganism found (184, 271). The rates of
MRSA colonization in the nares and
in wounds range from 8-53%, and 30-
82%, respectively (23). European
studies from the UK and Ireland sug-
gest that the rates of MRSA coloniza-
tion in long term care residents are
lower, from 0.81% to 17% (50, 79,
186, 204). Even if MRSA coloniza-
tion rates are high in long-term care
facilities, infections of MRSA may
occur infrequently. It has been sug-
gested that facilities with endemic
MRSA should perform routine sur-
veillance of MRSA infections and
uphold basic infection control practic-
es to prevent transmission. Knowledge
of the MRSA colonization status of
residents is not so necessary. Only
when a certain threshold of MRSA
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infections is reached, should more in-
tensive prevention measures, such as
screening and isolation, be implement-
ed until the chain of transmission is
disrupted (203, 204). Prevention mea-
sures for long-term care facilities with
non-endemic MRSA have not been
suggested. Some studies indicate that
MRSA strains isolated from long-term
care residents originate in the refer-
ring hospitals, since the strains show
phage types similar to hospital strains
(79).
Community acquisition of
MRSA has been described in rural
communities with a low socio-eco-
nomic status, e.g. among Australian
aboriginees, American Indians, and in
certain areas in New Zealand, Tonga,
and Samoa (72, 95, 160, 272). Out-
breaks of community MRSA have
been described among intravenous
drug users, members of a sports group,
and families (150, 152, 239). One out-
break of gastroenteritis has also been
attributed to a community MRSA
(125). The overall prevalence of com-
munity MRSA among urban homeless
and marginally housed adults, subject-
ed to crowded living conditions with
poor access to sanitation facilities, was
2.4%. However, the urban poor who
did not have known MRSA risk fac-
tors had an MRSA prevalence similar
to that of the general population (38).
Household pets may also carry MRSA
(151), and transmission to humans has
been suspected (32). Reports on
MRSA in the community are conflict-
ing. MRSA colonization in healthy in-
dividuals without MRSA risk factors
and health-care facility contacts seem
to be rare (4, 237, 249, 259). On the
other hand, MRSA caused the deaths
of four healthy children without any
known risk factors (29), and certain
patient groups are commonly colo-
nized with MRSA prior to hospital ad-
mission (72, 147, 238). These obser-
vations warrant wider investigations
on the frequency of, and risk factors
specific for, community acquisition of
MRSA. In contrast to MRSA strains
found in long-term care residents, oth-
er community-acquired MRSA usual-
ly show antibiotic resistance patterns
and genotypes differing from those of
hospital isolates (3, 95).
2.2.6 Molecular typing of MRSA
Molecular typing through phenotypic
or genotypic methods aims at defin-
ing whether a group of strains of a sin-
gle species is clonal, i.e. arises from a
common precursor. For MRSA, this
information is needed for various pur-
poses. In an outbreak investigation, an
increased number of spacially and
temporally related strains are typed in
order to identify whether the outbreak
is due to the spread of a single strain.
Molecular typing provides informa-
tion on changes in the MRSA popula-
tion during long-term surveillance,
after implementation of infection con-
trol measures, or after a change in an-
tibiotic prescribing policy. Typing is
also used to deduce evolution and glo-
bal spread of MRSA strains. A large
number of typing methods have been
developed over the past decades. The
choice of the typing method depends
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Method Target Principle Outcome 
Phage typing Cell surface 
components  
Infection of strains with phages, 
differentiation by ability of 
phages to lyse distinct strains 
Lytic plaques on bacterial lawn on 
plate 
Pulsed field gel 
electrophoresis 
Whole genome Total genomic digestion with 
infrequent cutters, followed by 
electrophoresis with periodic 
changes in the orientation of 
electric field 
Restriction fragment length 
polymorphism of total genomic 
DNA 
Ribotyping rRNA genes Total genomic digestion, 
followed by Southern 
hybridization with rDNA probe 
Restriction fragment length 
polymorphism based on the size 
and number of fragments that 
contain rRNA genes 
HVR-hybridization Hypervariable 
region within mec 
DNA 
Total genomic digestion, 
followed by Southern 
hybridization with probes 
recognizing the hypervariable 
region 
Restriction fragment length 
polymorphism based on the size 
and number of fragments that 
contain HVR-sequence 
Multilocus 
sequence typing 
Seven 
housekeeping 
genes  
Sequencing of each gene Nucleotide sequence 
 
Table 2. Basic principles of methods used for typing of MRSA in this study. Adapted from (221)
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on the purpose of the analysis (out-
break investigation, surveillance, evo-
lution studies), and on the biological
performance and technical efficiency
of the method (283) (Table 2). An op-
timal method for all purposes of typ-
ing should show high typeability, tech-
nical reproducibility, ease of interpre-
tation of results, and low cost. For out-
break investigations the general avail-
ability of the method and ease of per-
formance are of practical importance.
The discriminatory power should be
high for outbreak investigations, but
less high for population studies, oth-
erwise the clonal relationships may
remain obscure (74). Reproducibility
is particularly important if the typing
results are (electronically) stored and
later compared with new results.
Phenotypic typing methods
characterize the strain relations indi-
rectly through the expression of dif-
ferent genes. The results are often in-
fluenced by environmental factors.
Therefore phenotypic identity or sim-
ilarity is not always due to genomic
identity, and genomic identity is not
always reflected phenotypically.
Phage typing is one of the old-
est methods used for discrimination of
MRSA strains; the first set of phages
was established over 50 years ago
(208), and phage type data on histori-
cal S. aureus strains are available (82,
303). Phage typing is based on vari-
able capabilities of different bacte-
riophages to lyse different MRSA
strains (207). Although an internation-
al set of phages for S. aureus and an
additional set for MRSA have been
established, and standardization has
been attempted, this method shows
considerable inter-laboratory variation
and variable typeability, and requires
technical expertise (10, 164). Howev-
er, it is rapid and usually sufficiently
discriminative for short-term outbreak
investigations.
Antimicrobial sensitivity testing
has been a useful adjunct to MRSA
typing in short outbreaks caused by
multiresistant strains, since the anti-
biogram is often the first typing result
available (231). Different patterns pre-
dict different sources of infection.
However, the antimicrobial suscepti-
bility pattern of an individual strain
may change during treatment (126), or
because of antibiotic selection pres-
sure in hospitals.
Multilocus enzyme electro-
phoresis (MLEE) is based on electro-
phoretic mobility of several proteins
essential for cell viability and growth
(245). This method is not sufficiently
discriminative for outbreak investiga-
tions, but instead provides information
on population studies. Other pheno-
typic typing methods, such as biotyp-
ing, serotyping, polyacrylamide gel
electrophoresis (PAGE) analysis of
released or cell wall bound proteins,
and immunoblotting, can be used as
additional methods (244, 261). How-
ever, these methods are not often used
because of lack of appropriate repro-
ducibility or discriminatory power.
Genotypic typing is based on the
analysis of a chromosome or extrach-
romosomal DNA, allowing direct
comparison of genotypes between
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111). Additional discrimination can be
achieved by subsequent restriction
fragment length polymorphism
(RFLP) analysis. PCR amplification of
a tandem repeat region of the extra-
cellular part of staphylococcal coagu-
lase, and subsequent AluI digestion,
results in moderate discrimination of
strains (92, 261). The variation in the
protein A repeat units is also a target
for typing. Changes in the protein A
repeat region may, however, occur
more rapidly than the entire genome
evolves, and thus be an unsuitable tar-
get for purposes other than outbreak
investigation (280). The ribosomal
RNA sequences and the spacer se-
quence between 16S and 23S rDNA
have also been targets for PCR-based
typing. Another approach is to use as
PCR targets polymorphic non-coding
repetitive (ERIC or REP) sequences
scattered around bacterial genomes
(59). Arbitrarily primed PCR (AP-
PCR) and randomly amplified poly-
morphic DNA analysis (RAPD) are
based on short primers and low-strin-
gency amplification conditions. Am-
plification of random sequences forms
a PCR-pattern shared by identical
strains. Low-stringency PCR condi-
tions may reduce the reproducibility
of this method, and it is seldom suit-
able for ongoing epidemiological sur-
veillance, unless sophisticated equip-
ment, high techical skills, and means
for computerized data storage and in-
terpretation are available (201). Am-
plified fragment length polymorphism
(AFLP) is a PCR-typing method
recently adapted for discrimination of
strains. Analysis of plasmid profiles
or restriction fragment analysis of
plasmids has been used in outbreak
investigations. Although the method
is technically simple and feasible in
most laboratories, its use is restricted
because of its variable typeability and
discriminatory power.
The restriction of chromosomal
DNA with frequently cutting enzymes
and subsequent agarose gel electro-
phoresis provides a discriminative fin-
gerprint of the whole chromosome.
Owing to the large number of frag-
ments, the interpretation may be sub-
jective and therefore non-reproduc-
ible. The interpretation can be im-
proved by Southern blotting the DNA
fragments to membrane and by high-
lighting a subset of the fragments with
specific probes (278). The probes must
include both conservative (to provide
typeability) and variable (to retain dis-
crimination) sequence areas. Prefera-
bly the target sequence should occur
in multiple locations within the chro-
mosome. DNA sequences meeting
these criteria among MRSA strains
include ribosomal RNA operons,
Tn554, IS256, and  IS 257/IS431. In-
dividual hybridization with multiple
probes, each recognizing a single-copy
gene, such as those for most virulence
factors, can also be used, but this ap-
proach is fairly laborious.
Several typing methods based
on polymerase chain reaction (PCR)
have been developed. Specific genes
with polymorphic repeat regions, such
as coa- and spa genes, have been used
as targets for PCR amplification (80,
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bacteria (292). In this method, chro-
mosomal DNA is first digested with
frequent cutters, specific adapters are
then linked to the resulting fragments,
and a subset of the fragments is selec-
tively amplified using primers
recognizing the adapter sequence and
extending the original fragment by one
to three selective bases. The large
number of fluorecently labeled
amplicons is finally separated by
electrophoresis.
Binary typing is based on dif-
ferential hybridization of up to 12 se-
lected probes with different MRSA
strains. For each strain analyzed, 12
“yes” or “no” (1 or 0) results are ob-
tained (284). The suitable probes, hy-
bridizing only with a subset of char-
acterized MRSA strains, were initial-
ly identified by RAPD (285). The
method has proved to be useful in the
characterization of the genetic diver-
sity of MRSA clone, as well as in de-
tecting nationwide spread of one
MRSA clone (282, 286).
Pulsed field gel electrophoresis
(PFGE), introduced in 1984 (243), is
regarded as the “gold standard” meth-
od for distinguishing MRSA strains.
In this method, chromosomal DNA is
digested with infrequently cutting en-
zymes having recognition sequences
of six to eight bases in length. The di-
gestion yields large fragments of DNA
(20-800kb), which cannot be separat-
ed in conventional agarose gel elec-
trophoresis. In PFGE, the direction of
the electric field periodically chang-
es, which allows separation of DNA
fragments of up to 10 Mb in size. The
separation is primarily based on the
time needed for reorientation, longer
for larger than for smaller fragments,
instead of the speed of migration.
Comparison of whole genome
sequences would be the ultimate and
the most stringent typing method for
any bacterium. However, for the pur-
poses described above, whole genome
sequencing is not feasible. Instead,
identification of regions with both
conservative and variable sequencs is
needed.  The degree of variation de-
pends again on the purpose of typing.
For population analysis of MRSA,
multilocus sequence typing (MLST)
has been used successfully (161).
MLST is based on the sequencing of
seven “housekeeping” genes. A dis-
tinct number is assigned to each dif-
ferent sequence of the same allele, and
the allelic profile of the seven genes de-
fines a sequence type (ST). Isolates with
identical sequence types are considered
clonal with a high degree of accuracy
(74). For outbreak investigations,
sequencing a single discriminatory
locus, such as short sequence repeats
(SSR) in spa or coa genes (80), may
be more convenient and less costly.
Data storage and interpretation
issues are essential as massive vol-
umes of genotypic and phenotypic
data may be generated in both short-
term and long-term approaches. In ad-
dition, international comparison of
MRSA strains has become increasing-
ly relevant because of the pandemic
spread of MRSA strains. Despite es-
tablished interpretation criteria (262),
availability of sophisticated software
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packages, and several inter-laborato-
ry standardization initiatives for PFGE
(46, 281), inter-laboratory reproduc-
ibility is difficult to achieve. Although
software which transform bands math-
ematically to numerical values do ex-
ist, PFGE and other banding pattern
based methods are prone to bias due
to manual selection of  bands. There-
fore, databases based on binary output
or sequence of numbers or letters
would facilitate international
comparison of strains.
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3. AIMS OF THE STUDY
The purpose of this study was to in-
vestigate the molecular epidemiology
of methicillin-resistant Staphylococus
aureus in a low-prevalence country.
The phenotypic and genotypic char-
acteristics of Finnish MRSA isolates
were analyzed in order to gain new
insights into the short-term and long-
term evolution of MRSA. The specif-
ic aims were:
1. To elaborate a MRSA typing
scheme suitable for continuous
nationwide MRSA surveillance
in Finland.
2. To analyze trends of MRSA oc-
currence in Finland in the 1990s
and to analyze molecular char-
acteristics of isolates in order to
identify those linked to epidem-
ics.
3. To estimate the proportion of
isolates of community-acquired
MRSA in Finland, and to deter-
mine if any molecular type as-
sociates with community acqui-
sition.
4. To recognize internationally
spread MRSA clones in Finland,
to search for molecular traits
linked to the epidemic spread of
MRSA, and to analyze the
clonality of the most common
MRSA strains encountered in
Finland.
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4. MATERIAL AND METHODS
4.1 NATIONAL MRSA SUR-
VEILLANCE
Until 1995, data on the annual num-
bers of MRSA isolations were collect-
ed voluntarily on a weekly basis and
were available from the major micro-
biology laboratories, which included
those of all central and university hos-
pitals, as well as the major private lab-
oratories. Since 1995, microbiology
laboratories have reported MRSA iso-
lations, as well as all blood and cere-
brospinal fluid isolations of S. aureus,
to the National Infectious Disease
Register at the National Public Health
Institute (KTL). In this register, the
time interval within which S. aureus
isolates from the same person are in-
terpreted as one case is 36 months. The
following data concerning each isolate
are reported to the register: age and
gender of the patient, health care in-
stitution, date of isolation, and source
of positive culture.
4.2 MRSA STRAIN COLLEC-
TION
Since 1992, all microbiology labora-
tories have been asked to send all
MRSA isolates to the Laboratory of
Hospital Bacteriology at KTL. The
present study reports the analysis of
this population-based MRSA collec-
tion from 1992 to 2001 (Table 3).
Eighteen internationally characterized
epidemic MRSA strains were used as
controls. These strains were obtained
from the Harmony group (http://
www.phls.org.uk/International/Har-
mony/Harmony.htm), and included
type strains for Belgium EC-1
(97S96), Belgium EC-2 (97S99), Bel-
gium EC-3 (97S101), France A (162),
France B (97121), France C (10828),
Greece 1 (3680), Spain E1 (5), N. Ger-
man I (134/93), Hannover III (1000/
93), Berlin IV (825/96), UK EMRSA-
1 (NCTC 11939), UK EMRSA-3
(M307), UK EMRSA-15 (90/10685),
UK EMRSA-16 (96/32010), Pediatric
clone (HDE288), Brazilian clone
(HSJ216), and Iberian clone
(HPV107).
4.3 EPIDEMIOLOGICAL
BACKGROUND DATA
4.3.1 Hospital contacts
For publication III, the data on previ-
ous hospitalization periods of MRSA
positive persons were retrieved from
the National Hospital Discharge Reg-
ister (HILMO) at the National Re-
search and Development Centre for
Welfare and Health (STAKES).
HILMO is a civil register comprising
comprehensive health-care records
provided by all hospitals and health-
care centers in Finland, including out-
patient surgery. Each report to the reg-
ister includes patient identity informa-
tion, admission and discharge dates,
the code of the health-care provider,
the type of service, speciality, the place
(home or institution) from which the
patient came to the institution, and the
date of  the surgical procedures.
For MRSA positive persons re-
garding whom no HILMO reports
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could be found, additional background
information was collected by sending
questionnaires to infection-control
nurses at the relevant health-care fa-
cilities. The information collected in-
cluded: 1) whether the MRSA-posi-
tive person was a patient or a staff
member, 2) whether the specimen was
taken on a clinical or a screening ba-
sis, and 3) whether the screening sam-
ple was taken because of a hospital
contact abroad or because of an epi-
demic situation.
4.3.2 Patient days
Annual patient days in health care
were retrieved from public HILMO
(Net-HILMO, http://info.stakes.fi/net-
tihilmo), with no access to client spe-
cific information. A patient day was
defined as 24 h during which a patient
occupied a bed in a health-care insti-
tute. The admission and discharge
days together counted as one patient
day.
Table 3. MRSA isolates and methods used in the study.
Public
-ation 
Focus of study Selection criteria for 
Finnish isolates 
(number of isolates 
studied) 
Methods used 
I MRSA trends 
and 
identification of 
epidemic 
strains 
 
All isolates, one per 
person, isolated in 1992-
1997 (891) 
• Antimicrobial 
susceptibility 
• Phage typing 
• PFGE and ribotyping for 
a subset of strains 
 
II Molecular traits 
for epidemic 
spread  
All sporadic isolates 
from year 1995 (47), 
and representatives of 
intra- and interhospitally 
spread strains (25) from 
1992-1999 
 
• Ribotyping 
• Phage typing 
• Antimicrobial 
susceptibility 
• HVR hybridization for 
representatives of each 
ribotype  
 
III Community-
acquired 
MRSA 
All isolates, one per 
person, from 1997-1999 
(526) 
• PFGE 
• HVR hybridization for a 
subset of strains 
• Phage typing 
• Antimicrobial 
susceptibility 
• Search for 
hospitalization periods 
from the hospital 
discharge register 
(HILMO) and by a 
questionnaire 
 
IV  Clonality and 
evolution of 
MRSA 
Representatives of the 
most common strains in 
1997-1999 (14) 
• MLST 
• Mec regulatory region-
PCR  
• HVR sequencing 
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4.4 ISOLATION OF DNA, AND
PRIMERS USED
Total genomic DNA was prepared for
all PCR-methods, ribotyping, hyper-
variable region hybridization, and
MLST. DNA was purified using a
guanidium isothiocyanate method
(218) (Publication I-III), a Qiagen Tis-
sue Purification Kit (Qiagen, Germa-
ny), or a method using phenol chloro-
form elution (101) (Publication IV).
The primers used in the study
(Table 4) were purchased from Amer-
sham Pharmacia Biotech, England.
4.5 IDENTIFICATION AND
ANTIMICROBIAL SUSCEPTI-
BILITY TESTING OF MRSA
On reception at the Laboratory of
Hospital Bacteriology, all isolates sus-
pected of being MRSA were verified
for oxacillin resistance by disk diffu-
sion and MIC-tests (see 4.5.1) and/or
by mecA-PCR (see 4.5.2). Initially, S.
aureus species identification was ver-
ified only if the species identification
was suspected of being incorrect: an
atypical or mixed culture, or non-
typable by S. aureus phages. The iden-
tification methods included Slidex ag-
glutination test (BioMérieux, France),
nuc-PCR (see 4.5.2), coagulase test
(130), API Staph (BioMérieux,
France), API ID 32 Staph
(BioMérieux, France), and biochemi-
cal tests. Since 2000, all isolates have
been tested routinely for correct spe-
cies identification and methicillin re-
sistance by nuc- and mecA-PCRs, re-
spectively.
4.5.1 Antimicrobial susceptibility
testing
The antimicrobial susceptibilities were
tested by the disk diffusion method
after overnight incubation at 37°C on
Muller-Hinton agar plates according
to the guidelines recommended by the
NCCLS. The antimicrobials tested in-
cluded gentamicin, tobramycin, eryth-
romycin, clindamycin, chlorampheni-
col, ciprofloxacin, rifampin, fucidic
acid, trimethoprim-sulfamethoxazole,
tetracycline, mupirocin, and vancomy-
cin. Oxacillin resistance was deter-
mined by the disk diffusion method
after 24-48 h growth at 30°C. MIC of
oxacillin was determined by the E-test
according to the manufacturer’s in-
structions (AB Biodisk, Sweden).
4.5.2 mecA-PCR and nuc-PCR
mecA-PCR and nuc-PCR were per-
formed either separately as described
earlier (24, 182) or as a multiplex ap-
plication. A 50 µl volume of PCR re-
action mixture contained 1 µl of puri-
fied genomic DNA, 50 pmol of each
of the nuc- and mecA-primers, 0.2 mM
of dNTP, 1 U of  DynaZyme poly-
merase (Finzymes, Finland), and 5 µl
of 10x buffer containing 15 mM of
MgCl2. The PCR amplification proto-
col included initial denaturation at
96°C for 10 min, followed by 40 cy-
cles of denaturation at 96°C for 30 s,
annealing at 46°C for 30 s, and exten-
sion at 72°C for 2 min, and final ex-
tension at 72°C for 5 min. The result-
ing amplicons were run in a 1.5% Sea
Kem agarose gel (BMA, USA) at 90V
for 1 h.
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Primer Sequence 5’→3’ Reference 
mecA, forward 
mecA, reverse 
AAAATCGATGGTAAAGGTTGGC 
AGTTCTGCAGTACCGGATTTGC 
(182) 
nuc, forward 
nuc, reverse 
GCGATTGATGGTGATACGGTT 
AGCCAAGCCTTGACGAACTAAAGC 
(24) 
arcC-Up 
arcC-Dn 
aroE-up 
aroE-Dn 
glpF-Up 
glpF-Dn 
gmk-Up 
gmk-Dn 
pta-Up 
pta-Dn 
tpi-Up 
tpi-Dn 
yqiL-Up 
yqiL-Dn 
TTGATTCACCAGCGCGTATTGTC 
AGGTATCTGCTTCAATCAGCG 
ATCGGAAATCCTATTTCACATTC 
GGTGTTGTATTAATAACGATATC 
CTAGGAACTGCAATCTTAATCC 
TGGTAAAATCGCATGTCCAATTC 
ATCGTTTTATCGGGACCATC 
TCATTAACTACAACGTAATCGTA 
GTTAAAATCGTATTACCTGAAGG 
GACCCTTTTGTTGAAAAGCTTAA 
TCGTTCATTCTGAACGTCGTGAA 
TTTGCACCTTCTAACAATTGTAC 
CAGCATACAGGACACCTATTGGC 
CGTTGAGGAATCGATACTGGAAC 
(73) 
mecI forward 
mecI reverse 
mecR1 penicillin binding domaine, forward 
mecR1 penicillin binding domaine, reverse 
mecR1 transmembrane domaine, forward 
mecR1 transmembrane domaine, reverse 
AATGGCGAAAAAGCACAACA 
GACTTGATTGTTTCCTCTGTT 
GTCTCCACGTTAATTCCATT 
GTCGTTCATTAAGATATGACG 
CAGGGAATGAAAATTATTGGA 
CGCTCAGAAATTTGTTGTGC 
(260) 
Druforward  TCTGAAGCAGCTTTAAATGATG Publication IV 
ISP3TT  TTACTTTAGCCATTGCTACCTT (200) 
 
Table 4. Primers used in the study
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4.6 TYPING METHODS
4.6.1 Phage typing
Phage typing was performed with an
international set of phages (207), pur-
chased from Statens Serum Institut,
Copenhagen, Denmark, at 1x and
100x routine test dilutions, both with
and without heat treatment, 55°C for
3 min, of the bacteria (53). The phage
pattern was defined on the basis of the
weakest test dilution that produced
clear lytic reactions. A minimum of
20 lytic plaques (++ reaction) was re-
quired to define a positive reaction for
each phage.
All isolates included in this
study were typed by phages. In publi-
cation I, the identification of epidem-
ic strains was primarily based on ph-
age typing.
4.6.2 Ribotyping
Ribotyping was performed as de-
scribed in publication I. Briefly, ge-
nomic DNA was digested separately
with one to three restriction enzymes,
HindIII, EcoRI, and ClaI (Boehringer
Mannheim, Germany). DNA frag-
ments were separated by electrophore-
sis, transferred to nylon membrane
(Boehringer Mannheim), and hybrid-
ized with digoxygenin labeled plasmid
pKK3535 containing the rrn operon
of Escherichia coli (25). Digoxygen-
in labeled DNA marker III (Boehring-
er Mannheim, Germany) or MluI di-
gested Citrobacter koseri (94) was
used as the molecular weight standard.
A difference of one band in a ribotype,
as detected by visual analysis, was
considered to represent a new type. An
arbitrary identification letter was as-
signed to each ribotype obtained by
different enzymes.
In publication I, ribotyping was
used to characterize further the isolates
suspected of being linked to epidem-
ics, and those nontypable by phages.
In publication II, ribotyping by EcoRI
was used for genomic characterization
of all isolates with unique phage pat-
terns (sporadic isolates) from the year
1995. In publication III, ribotyping
was used to verify the relatedness of
isolates from the years 1997-1999 if
results from PFGE and phage typing
were ambiguous.
4.6.3 Pulsed field gel electro-
phoresis (PFGE)
The genomic DNA was prepared in
agarose blocks as described previously
(89, 209) with slight modifications
described in publication I. Briefly, a
0.5 ml volume of logaritmic phase
cells and an equal volume of 2% Sea-
Plaque agarose (FMC Bioproducts,
USA) were mixed and solidified. The
DNA purification protocol included
lysostaphin and proteinase K treament,
followed by washing steps with phe-
nylmethylsulfonyl fluoride and TE
buffer (10 mM Tris and 1 mM EDTA,
pH 8.0). Restriction fragment length
polymorphism following SmaI-diges-
tion was detected with Chef DR III,
Chef Navigator, or Chef Mapper (Bio-
Rad, USA) for 24 h, on 1% SeaKem
agarose gel (FMC BioProducts, USA)
at 6 V/cm with initial and final switch-
ing times of 10 s and 60 s, respective-
ly. A Lambda Ladder PFG marker
(New England BioLabs, USA) was
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used as the molecular weight standard.
Since 2001, the Harmony PFGE pro-
tocol has also been used for analysis.
In the Harmony protocol the chromo-
somal DNA fragments are separated
by two phases: phase 1 for 10 h, with
the initial and final switching times of
5 s to 15 s; and phase 2 for 13 h, with
15 s to 60 s, respectively. The molec-
ular weight standard in the Harmony
protocol is S. aureus NCTC 8325. Oth-
erwise the method was performed as
above. PFGE profiles differing by
fewer than four bands were interpret-
ed as identical or closely related (262)
In publication I, PFGE was used
to characterize further the suspected
epidemic strains and the isolates non-
typable by phages. In publication III,
all isolates from the years 1997-1999,
showing differences in phage typing,
were typed by PFGE.
4.6.4 Hypervariable region
(HVR) hybridization
The genomic DNA was digested with
EcoRI and BglII restiction enzymes,
and hybridized with two probes pre-
pared from plasmid pBBB30 (233).
HVR probe I is a 3.6-kb fragment that
recognizes the HVR of the mec DNA,
starting within the mecA gene and
reaching up to IS431 mec. HVR probe
II is a 1.5-kb fragment digested with
HindIII from the 3.6-kb fragment. This
probe recognizes the direct repeat unit
(dru) -region and an E. coli ugpQ-like
sequence within the mec DNA. The
digoxigenin-labeling of the probes,
eletrophoresis and blotting to nylon
membrane of genomic DNA frag-
ments, and hybridization were per-
formed as described in publication II.
Digoxygenin-labeled molecular
weight marker III (Boehringer Man-
nheim, Germany) or Citrobacter kos-
eri (94) was used as the molecular
weight marker.
The HVR-hybridization was
performed on representatives of dif-
ferent ribotypes identified in sporadic
isolates from the year 1995, as well as
on all epidemic and local outbreak
strains identified before the year 2000
(publication II). Equally, the HVR-hy-
bridization with HVR probe I was per-
formed on all representatives of the
most common MRSA strains from the
years 1997-1999 (publication III).
4.6.5 Multilocus sequence typing
Multilocus sequence typing was per-
formed as previously described (73).
Internal fragments of seven house-
keeping genes [carbamate kinase
(arcC), shikimate dehydrogenase
(aroE), glycerol kinase (glpF), guany-
late kinase (gmk), phosphate acetyl-
transferase (pta),  triosephosphate
isomerase (tpi), and acetyl coenzyme
A acetyltransferase (yqiL)] were am-
plified by PCR. The PCR products
were purified, and the sequences of
both strands (or occasionally of one
strand only) were determined by ABI
Prism 310 Genetic Analyzer using the
BigDye fluorecent terminator chem-
istry (Applied Biosystems, UK). The
forward and reverse sequencing prim-
ers for each gene fragment were the
same as those used for the initial PCR.
The allele numbers were assigned to
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each loci by the MLST database (http:/
/www.mlst.net) and allelic profiles,
defining the sequence types (STs) for
each strain, were compared with those
available in the database and with
those found in the literature.
The MLST was used to delin-
eate the clonality and evolution of the
most common Finnish MRSA strains
identified during 1997-1999 (publica-
tion IV)
4.6.6 mec regulatory region PCR
Using primers and a PCR protocol
described earlier (260), three different
fragments within the mec regulatory
region were separately amplified. The
fragments were: 1) almost the entire
mecI gene, 2) the penicillin binding
domaine of the mecR1 gene, and 3)
the membrane spanning domaine of
the mecR1 gene. The resulting ampli-
cons were run and detected in agarose
gel.
4.6.7 mec hypervariable region
sequencing
The direct repeat region (dru) between
the glycerophosphoryl diester phos-
phodiesterase (ugpQ)-like sequence
and IS431 was amplified by using
primers Druforward and ISP3TT. The
Druforward primer was designed on
the basis of mec sequence data in the
EMBL database (accession no.
Y14051), and the ISP3TT primer was
modified from an ISP3 primer de-
scribed previously (200). The purified
amplicons were sequenced by ABI
310 by using BigDye fluorescent ter-
minator chemistry (Applied Biosys-
tems, Warrington, UK). The sequenc-
ing primers were the same as those for
the initial PCR.
4.6.8 Computer-assisted analysis
of typing data
Computer-assisted analysis of PFGE
types and ribotypes was performed by
BioNumerics, version 1.0 or 2.0 (Ap-
plied Maths, Belgium), using Dice
coefficient and UPGMA (unweighted
pair group method using arithmetic
averages).
4.7 DEFINITIONS AND NO-
MENCLATURE OF STRAINS
Strain types were identified on the
basis of the phage pattern (publica-
tions I and II), ribotype (publications
II and III), and PFGE type (publica-
tion III). The strain types of two iso-
lates were considered to be the same
if the phage types were similar and the
ribotypes were identical and/or the
PFGE types differed by fewer than
four bands. Multiresistance was de-
fined as resistance to more than three
antimicrobial groups other than beta-
lactams, and multisensitivity as resis-
tance up to three antimicrobial groups
other than beta-lactams.
A sporadic strain of MRSA was
defined as a strain isolated from one
person only and displaying a unique
antimicrobial susceptibility and/or
strain type (publications I-IV). MRSA
isolates sharing the same strain types
and isolated from two or more persons
in the same hospital were defined as
representatives of local outbreak
strains (publications I and II). MRSA
isolates sharing the same strain type
44
and isolated from two or more persons
at two or more hospitals were defined
as representatives of an epidemic
MRSA strain (publications I and II).
In this study, a clone was defined
as a group of MRSA strains the mem-
bers of which are most probably de-
scendants of a single ancestor. To be
classified as members of the same
clone, isolates had to have identical or
single locus variant MLST profiles, or
ribotypes differing by fewer than four
bands, and PFGE patterns differing by
less than seven bands (publications III
and IV). Clone assignment by PFGE
was not performed if more than seven
band differences occured. A clone may
contain different epidemic or local
outbreak strains.
Unless an international name for
a strain was known, each epidemic
strain and clone was named accord-
ing to the city/region where the strain
was first isolated or suspected of hav-
ing been imported from. For interna-
tional communication, an identifica-
tion code number was given to each
local outbreak strain and epidemic
strain.
An MRSA isolate was defined
as community acquired if the MRSA-
positive specimen was obtained out-
side hospital settings or within 2 days
of hospital admission, and if it was
from a person who had not been hos-
pitalized within 2 years before the date
of the MRSA isolation (publication
III).
4.8 STATISTICAL ANALYSIS
AND ETHICAL ASPECTS
For categorigal variables, proportions
were compared by the chi-square test
with Yates’ correction or by Fisher’s
exact test, as appropriate. The means
and medians of the continuous vari-
ables were compared by Student’s t
test or Mann-Whitney U test, depend-
ing on the sample distribution.
On the approval of the Finnish
Ministery of Social Affairs and Health
and of the data protection authority,
the National Research and Develop-
ment Centre for Welfare and Health
gave us permission to use the data
from the HILMO register.
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5. RESULTS
5.1 ELABORATION OF MRSA
VERIFICATION AND TYPING
(I, II, III, IV)
Table 5 shows the methods used for
the verification and typing of MRSA
isolates at the KTL Laboratory of
Hospital Bacteriology during the years
1992-2002. The current scheme in-
cludes species verification and methi-
cillin-resistance verification by mul-
tiplex mecA-nuc-PCR, antimicrobial
sensitivity testing, and typing by ph-
ages and by PFGE. Ribotyping is used
in cases of ambiguity between PFGE
and phage typing results (Figure 6).
MLST is available for identifying the
genetic background of emerging epi-
demic strains.
Results of MRSA verification
and typing are reported to the refer-
ring laboratory and to the infection
control nurse of the relevant health-
care facility. Reception of notification
at the National Infectious Disease
Register of each confirmed MRSA is
concurrently verified.
Table 5. Elaboration of the MRSA verification and typing at the Laboratory of Hospital Bac-
teriology, KTL.
Purpose Methods Year 
  92     93     94     95     96     97     98     99    00     01     02 
Identification Slidex 
Coagulase 
Nuc-PCR 
API Staph, API ID 32 
Other biochemical tests 
Antimicrobial    
resistance 
Oxa disk diffusion 
Oxa E-test 
Antibiogram 
MRSA Screen 
MecA-PCR 1) 
Typing Phage typing 
PFGE 2) 
Ribotyping 
MLST 
 
Performed selectively on a subset of isolates, performed routinely
on all isolates. 1) Until 1997, and between 1997 and 1999, mecA-PCR was performed on
isolates having an oxacillin MIC of 1-6 µg/ml, and ≤64 µg/ml, respectively. 2) PFGE was
performed retrospectively in 1997-1999.
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5.2 MRSA TRENDS AND EPI-
DEMIC STRAINS (I, II, III, IV)
On the basis of the data received from
major microbiology laboratories, the
number of isolates received for typ-
ing in the Laboratory of Hospital Bac-
teriology, and the MRSA notifications
to the National Infectious Disease
Register, the annual number of MRSA
isolations ranged from 89 to 340 dur-
ing 1981-2001 (Figure 7).
Between 1995 and 2001, 1322
MRSA isolations were reported to the
National Infectious Disease Register.
The median age of MRSA positive
persons was 58 years (range <1-98),
and 51% (674) were male. Fourty-four
Figure 6. MRSA verification and typing scheme at KTL, and the system of reporting to
laboratories.
Figure 7. Number of MRSA isolations in Finland during 1981-2001.
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% (577) of the isolations were from
persons of 60 years of age or older,
and 10% (131) were from children
under the age of 16. The incidence of
MRSA ranged from 1.7 per popula-
tion of 100,000 in 1995 to 5.0 in 2000
(Table 6). In 1995, 70% (69/89) of all
notifications were received from the
Helsinki metropolitan area, and 11 of
21 hospital districts reported no
MRSA isolations. By 2001, all but two
hospital districts reported MRSA, and
the majority of notifications were out-
side the Helsinki metropolitan area
(Figure 8). During 1995-2001, the pro-
portion of methicillin resistance
among S. aureus blood isolates re-
mained at a level of 1% or less.
Table 6. Incidence and age distribution of MRSA cases in1995 through 2001
Figure 8. Number of annual MRSA isolations by hospital district in 1995 through 2001.
Number of MRSA isolations: =0, =1-10,     >10.
1995  1998      2001
NA. Not applicable, since denominator data were not available.
Year Number of
MRSA
notifications
MRSA
incidence per
population of
100,000
MRSA
incidence
per 100,000
patient days
Median
age,
years
Number of
persons
<16 years
(%)
Number of
persons
 65 years
(%)
1995 89 1.7 NA 65 6 (7) 47 (53)
1996 108 2.1 7.11 63 10 (10) 52 (48)
1997 120 2.3 8.10 52 13 (11) 49 (41)
1998 189 3.7 12.93 51 20 (11) 54 (29)
1999 211 4.1 14.77 57 23 (11) 87 (41)
2000 261 5.0 18.47 61 25 (10) 122 (47)
2001 344 NA NA 63 34 (10) 166 (48)
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During the period of this study,
from 1992 to 2001, a total of 1847
S.aureus isolates were verified as
MRSA and typed. Of all isolates, 79%
(1457 of 1847) were classified as epi-
demic or local outbreak strains. The
proportion of sporadic isolates during
the periods 1992-1997 and 1997-1999
were 46% (345/748) on the basis of
phage typing, and 11% (56/526) on the
basis of phage typing and PFGE, re-
spectively.
During 1992-2001, a total of 26
different epidemic and 12 local out-
break strains were identified (Table 7).
Fourteen (54%) of the epidemic strains
and 5 (41%) of the local outbreak
strains were multiresistant, i.e. resis-
tant to more than three antimicrobial
groups other than beta lactams. Ri-
botyping by HindIII, EcoRI, and ClaI
divided the strains into 20, 18, and 15
different types, respectively, and a
combined analysis yielded 23 ri-
botypes. PFGE differentiated the
strains into 29 distinct types and into
9 subtypes with no more than four
band differences. Computer-assisted
analysis of the PFGE types of the ep-
idemic and outbreak strains revealed
8 clusters of strains with similarity val-
ues of at least 75%.
Two epidemic strains were iso-
lated from more than 200 persons, and
another seven strains caused epidem-
ics involving 50-100 persons. The
largest epidemic, caused by the strain
Helsinki I, occurred in Southern Fin-
land and involved 270 persons. The
epidemics started in 1992, peaked in
1994, and declined within a few years.
However, this strain is still isolated oc-
casionally, although most of the cur-
rent isolates exhibit subtype level vari-
ation, or 4 to 7 band differences in
PFGE as compared with the original
epidemic strain. The other highly prev-
alent epidemic strain, Mikkeli II,
emerged in several hospitals simulta-
neously in 1997. The detection of its
emergence was delayed, since the iso-
lates from different parts of the coun-
try exhibited wide variation in phage
types, and no epidemiological linkage
between isolates from different areas
was apparent. Along with comprehen-
sive, but retrospective, PFGE analy-
sis of isolates from 1997 to 1999, the
genomic relatedness among these ep-
idemiologically unrelated isolates was
detected.
Hypervariable region hybridiza-
tion with HVR probe I differentiated
the epidemic and local outbreak strains
into 4 types: A, B, C, and D, each of
which consisted of two bands. The
HVR probe II recognized one of these
two bands, showing the position of dru
and flanking sequences. Multisensi-
tive strains had the mec HVR hybrid-
ization pattern A. The only exception
to this was the strain Helsinki III,
which was multiresistant and still had
HVR-type A. HVR types B, C, and D
were found in multiresistant strains. A
single multisensitive strain (Turku IV)
with HVR-type C was identified.
Strains showing HVR type A and B
were negative in mecI-PCR. Sequenc-
ing of the dru region within HVR was
performed on representatives of HVR
types A, B, C, and D. Sequencing con-
firmed that HVR types B and D had a
deletion of about 1000 kb as compared
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with strains with other HVR types.
The dru sequences were highly simi-
lar within each HVR type and within
HVR types B and D together.
5.3 MOLECULAR TRAITS
LINKED TO EPIDEMIC
SPREAD (II)
Ribotyping, with EcoRI restriction
enzyme, of 72 strains, including all
sporadic MRSA isolates from the year
1995 and the local outbreak and epi-
demic strains identified during 1992-
1999, revealed 18 different ribotypes.
The two most prevalent types, differ-
ing from each other by one band, made
up 49% (35/72) of all strains. Of the
sporadic strains, 45% (21/47) showed
either of these types. Corresponding
figures for epidemic and local out-
break strains were 64% (9/14) and
45% (5/11), respectively.
Hypervariable region hybridiza-
tion with HVR probe I differentiated
the 72 strains into 7 types: A, B, C, D,
E, F, and G. Most of the sporadic iso-
lates were either of HVR type A (22/
47, 47%) or HVR type C (16/47,
34%). The epidemic strains were
mostly of HVR type B (4/14, 29%) or
type C (6/14, 43%). Of the local out-
break strains, 7 (64%) were of HVR
type A.
Of the sporadic strains, 30% (14/
47) were multiresistant, whereas for
the epidemic, and the local outbreak
strains the corresponding figures were
79% (11/14) and 45% (5/11), re-
spectively. Multiresistance was more
common among epidemic than among
non-epidemic strains (11/14 vs. 19/58,
p<0.005)
In a combined analysis of anti-
biotic susceptibility and genotype, the
MRSA strains clustered into two main
groups. One group included strains
showing mec HVR hybridization pat-
tern A combined with a variety of ri-
botypes and resistance to beta lactam
antibiotics only. The majority of these
strains were sporadic by nature. The
other group included strains with mec
HVR hybridization patterns B or C in
association with the two major ri-
botypes. This group included both ep-
idemic and sporadic strains.
5.4 MRSA CLONES (I, III, IV)
Of all 38 local outbreak and epidemic
strains, genotyping classified 31
strains into 8 clones (Table 7). On the
basis of MLST, representatives of sev-
en of these clones were found to be
identical with the internationally
known S. aureus clones: ST 247, ST
239, ST 36, ST 22, ST 5, ST 45, and
ST 12. The first six clones are also
known as the Iberian, Brazilian, UK
EMRSA-16, UK EMRSA-15, New
York (or Pediatric), and Berlin clones.
The ST12 clone was named Joensuu
clone in Finland. On the basis of ri-
botypes and/or clustering by PFGE,
six of the remaining seven strains also
belong to either the Brazilian clone or
to the Iberian clone. Finally, the Hels-
inki VIII strain was a triple allele
MLST variant of Joensuu II, and may
thus belong to the Joensuu clone, al-
though the definition for a clone used
in this study (see section 4.7), would
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Clone Strain  
identification 
Number 
of 
isolates 
Year of 
first 
isolation 
in 
Finland 
 
 
Geographical 
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 Name  Id. no          
Brazilian Helsinki VI 
Helsinki VII 
Lohja 
Kokkola 
Pori II 
E19 
E20 
E24 
E27 
O16 
15 
12 
62 
78 
3 
1998 
1998 
1998 
1997 
1993 
South 
South 
South 
Many regions 
West 
Yes 
Yes 
Yes 
No 
No 
1 
2 
3 
4 
4b 
I 
- 
III 
II 
II 
B.b:d 
C:a:e 
B:b:d 
A:a:e 
AN:a:e 
C 
C 
C 
A 
A 
239 
239 
241, 239 slv 
8, 239 slv 
Iberian Turku I 
Turku II 
Turku III 
Kotka 
Kerimäki 
Tampere III 
E6 
E7 
O8 
E10 
O29 
O25 
40 
62 
2 
32 
34 
15 
1991 
1992 
1992 
1992 
2000 
1998 
West 
West 
West 
East 
East 
Central 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
5 
5b 
5c 
5d 
6 
7 
III 
III 
III 
III 
III 
- 
A:a:e 
B:b:d 
B:b:d 
B:b:d 
A:a:e 
A.a:e 
B 
B 
B 
B 
B 
 
247 
 
 
 
247 slv 
New York 
(or Pediatric) 
Helsinki I 
Koskela 
Bel EC-3 
Moscow  
Helsinki III 
E1 
O26 
E34 
E32 
O3 
270 
5 
33 
3 
6 
1992 
1999 
2001 
2000 
1994 
South 
South 
Many regions 
Many regions 
South 
Yes 
Yes 
Yes 
Yes 
Yes 
8 
9 
10 
11 
12 
IV 
IV 
IV 
IV 
- 
I:g:e 
I:g:e 
CH:cb:e 
A:a:e 
F:g:e 
D 
D 
 
 
A 
5 
 
Table 7. MRSA clones and strains during 1992-2001 in Finland
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UK EMRSA-16 Helsinki V 
Pori I 
E5 
E15 
75 
32 
1995 
1993 
South 
Many regions 
Yes 
No 
13 
13b 
V 
V 
AR:af:q 
AF:j:y 
C 
A 
36 
30, 36 slv 
Mikkeli Tampere I 
Mikkeli I 
Mikkeli II 
Karkkila 
E12 
O11 
E23 
O37 
54 
51 
241 
7 
1994 
1993 
1997 
2000 
Central 
East 
Many regions 
South 
No 
No 
No 
No 
14 
14b 
14c 
15 
VI 
VI 
VI 
- 
AP:ad:c 
AP:ad:c 
AP:ad:c 
AP:ad:c 
A 
A 
A 
 
 
59 slv 
Berlin  Kemi 
Kajaani 
Joensuu I 
Pello 
Berlin IV 
E17 
O18 
E21 
E28 
E38 
50 
11 
8 
35 
13 
1996 
1997 
1996 
2000 
1998 
Many regions 
North 
East 
Many regions 
Many regions 
No 
No 
No 
No 
No 
16 
16b 
16c 
17 
18 
VII 
VII 
VII 
VII 
VII 
AG:aa:r 
BB:g:r 
AW:bo:n 
CC:bs:ax 
CG::aa:r 
A 
A 
A 
45 
Joensuu Joensuu II 
Nurmes 
Vaalijala 
E22 
E36 
O33 
20 
2 
32 
1998 
2001 
2001 
Many regions 
East, South 
East 
No 
No 
No 
19 
20 
21 
VIII 
VIII 
VIII 
AH:z:v 
CJ:ch:h 
AH:ci:e 
A 12 
UK EMRSA-15 UK EMRSA-15 E30 44 1997 Many regions No 22 - CB:br:al A 22 
Undefined 
(Iberia or Brazil) 
Helsinki II 
Helsinki IV 
Lithuania 
Seinäjoki 
Tampere II 
Turku IV 
E2 
O4 
E35 
E14 
E13 
O9 
36 
3 
4 
5 
19 
25 
1993 
1994 
2000 
1992 
1994 
1993 
South 
South 
South, East 
West 
Central 
West 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
23 
24 
25 
26 
27 
28 
- 
I 
I 
I 
- 
- 
A:a:j 
A:a:z 
A:a:e 
B:b:d 
B:b:d 
A:b:d 
B 
C 
 
C 
C 
C 
 
Undefined Helsinki VIII E31 18 1997 Many regions No 29 - Bz:ax:h A New 
 
1) PFGE types and subtypes, ≤4 bands difference
2) Cluster of strains with ≥75% similarity level by Bionumerics (dice coefficient, UPGMA, tolerance 1-2%)
3) Blank, not determined
52
not allow this assignment. For four
clones (Iberian, Brazilian, New York,
and Berlin), other strain types showing
four to seven PFGE band differences
as compared with epidemic and local
outbreak strains have been identified.
Within one and the same clone,
antimicrobial resistance patterns of
different strains were mostly similar.
A few exceptions were found: 1)
Kokkola, Pori I, and Kerimäki strains,
which showed multisensitive patterns
in contrast to multiresistant patterns of
all other members of the correspond-
ing clones, 2) Pello strain, which
showed two patterns, multiresistant
and multisensitive, and 3) Helsinki V
and Pori I strains, which constituted
one clone, but showed different anti-
microbial resistance patterns. Strains
repeatedly isolated during long time
periods (Helsinki I, Helsinki V, Kemi)
showed changes in their antimicrobi-
al resistance patterns.
5.5 MRSA IN COMMUNITY
(III)
In 1997-1999, MRSA was isolated
from 526 persons. Their median age
was 51 years (range 0-96), and 291
(55%) were male. Of all 526 persons,
108 (21%) did not have any verified
link to health-care facilities within two
years before the MRSA isolation date.
Their MRSA isolates were classified
as community acquired. The HILMO
register and the questionnaire survey
showed 418 (79%) persons who had
at least one contact with a hospital, and
their MRSA isolates were classified
as hospital acquired. The median age
of the persons who did not have any
contact with a health-care facility was
lower than that of the persons who did
(34 vs. 58 years, p<0.01).
Among the 526 MRSA isolates,
the typing scheme showed 84 strain
types, 56 of which were sporadic and
28 were shared by at least two persons.
The distributions of sporadic (in total
56/526, 11%) and shared (in total 470/
526, 89%) strain types was similar in
persons with (43/418, 10%) and with-
out (13/108, 12%) connections to
health-care facilities.
Fourteen strain types, each of
which was isolated from ten or more
persons, represented 80% (421/526) of
all MRSA isolations. Three of the 14
common strain types were more like-
ly to be found in persons who did not
have a contact with a health-care fa-
cility than in those who did have such
a contact: Mikkeli clone, Helsinki
VIII, and Joensuu II. Of all strains iso-
lated from persons who had no hospi-
tal contact, 94% were multisensitive.
Of the 56 sporadic strains, 41% were
multisensitive.
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6. DISCUSSION
6.1 ELABORATION OF THE
TYPING SCHEME
Comprehensive typing of all MRSA
isolates, or any particular nosocomial
pathogen, has been considered unnec-
essary or even useless: “At best, such
an expenditure of time, effort, and
money provides some degree of infor-
mation on the baseline genotypes of
organisms in nosocomial environ-
ment. At the worst, the result is a
mountain of data, which is difficult to
interpret in the absence of clear driv-
ing epidemiological question” (88).
However, we describe a typing scheme
suitable for assisting in continuous
nationwide MRSA surveillance. In
addition to providing baseline infor-
mation on genotypes for the whole
country, and assistance in local out-
break investigations, this scheme has
brought new information on the evo-
lution and clonality of the Finnish
MRSA. It is possible to conduct such
intensive typing only in countries with
low MRSA prevalence, and naturally
this scheme needs to be subjected to
constant evaluation and revision as
new methods become available.
It was estimated that the propor-
tion of sporadic strains was higher
during 1992-1997 than during 1997-
1999. This difference may not be real,
since for the first period the sporadic-
ity was mostly determined on the ba-
sis of phage typing. The reproducibil-
ity of phage typing is not sufficient for
long-term surveillance, since, as
shown by a recent study, fewer than
one half of the same isolates typed on
different days show identical reac-
tions, or show reactions differing in
strength only (10). The value of ph-
age typing results for individual labo-
ratories is also questionable. Since
only strong reactions (++ or greater)
are reported, a difference merely in the
strength of the reactions of a group of
strains may lead to incorrect interpre-
tation. Therefore, the use of phage typ-
ing for surveillance purposes should
be reconsidered. However, since ph-
age typing performs well in short out-
break investigations (208), and is
available only at KTL in Finland, it
continues to be part of our routine typ-
ing scheme.
A more reliable identification of
strains with similar genetic back-
grounds was achieved by inclusion of
PFGE in the routine typing scheme.
The current widely accepted guide-
lines for interpreting PFGE patterns
are restricted to outbreak investiga-
tions within a limited time frame
(262). Our decision to use PFGE and
the same guidelines also for continu-
ous MRSA surveillance was based on
several reasons: 1) PFGE was regard-
ed as a gold standard method for the
typing of MRSA; 2) the same method
could be used for both outbreak inves-
tigations and surveillance; 3) comput-
er-assisted analysis, storage of data,
and comparison functions were avail-
able; 4) long-term reproducibility of
other DNA-based typing methods,
such as RAPD, might be more diffi-
cult to achieve (273); and 5) a less dis-
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criminative method, ribotyping, was
available for isolates showing PFGE
patterns difficult to interpret.
MLST is not sufficiently dis-
criminative for local outbreak inves-
tigations, where the question is wheth-
er patient-to-patient transmission has
occurred. In addition, MLST is too la-
borious and time consuming for inten-
sive surveillance in which every new
MRSA isolate is typed. However,
when a new epidemic strain emerges,
MLST is a powerful tool for determin-
ing whether the same clone has been
encountered previously elsewhere,
and for investigating the evolutionary
origin of the emerging strain. In order
to optimize the global comparison of
pathogenic isolates, essential informa-
tion, such as geographical prevalence
and distribution, virulence properties,
and antimicrobial resistance data for
each pathogen, should be provided.
This process has already begun for
MRSA, Neisseria meningitidis, and
antibiotic-resistant pneumococci (161,
169).
The current typing scheme does
not include any method for typing mec
DNA. However, according to the
present study and recent reports (107,
198, 199), comprehensive assignment
of MRSA lineages requires identifi-
cation of both the genetic bacground
of the strain and the structural type of
the associated mec DNA. A multiplex
PCR method (197), recently devel-
oped for rapid identification of the
structural types of mec DNA, should
be evaluated, using the Finnish MRSA
strain collection, for its potential in-
clusion in the routine typing scheme.
6.2 MRSA TRENDS AND EPI-
DEMIC STRAINS
Until 1997 the number of MRSA iso-
lations remained stable, with a base-
line of 100-150 annual isolations. A
peak in 1994 (225 isolations) was due
to the spread of the Helsinki I epidemic
strain in the Helsinki metropolitan
area. Some uncertainty remains about
the data collected prior to 1995, since
the diagnostic criteria for detecting
methicillin resistance and the guide-
lines for weekly reporting of MRSA
were not well described. Since the es-
tablishment of the National Infectious
Disease Register in 1995, a continu-
ous increase in MRSA numbers has
been detected. The MRSA numbers of
the first three years of the National
Infectious Disease Register (1995-
1997) remained within the baseline of
the previous decade, but has exceed-
ed that since 1998. This increase may
be partly due to enhanced diagnostics
and a general awareness of MRSA. In
1995, MRSA isolations were mostly
reported from the hospital districts
with the highest population densities.
By 2001, MRSA isolations were re-
ported from all over the country.
A reliable comparison of MRSA
trends with other countries is difficult,
since proper denominator data are
rarely available for analyses. Accord-
ing to one year’s nationwide surveil-
lance in Switzerland, this country and
Finland had a similar incidence of
MRSA in 1997, 9.3 vs. 8.1 per 100,000
patient days, respectively (20). In Can-
ada, the incidence of MRSA during the
period 1996 to 1999 was higher than
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in Finland, but both countries experi-
enced a similar rate of increase. In
Canada, the number increased from
12.7 per 100,000 patient days in 1996
to 22.6 per 100,000 patient days in
1999 (251). The corresponding figures
in Finland were 7.1 in 1996 and 18.1
in 1999. The median age of MRSA
positive persons was lower in Finland
than in Canada, 58 vs. 71, respective-
ly. However, there are differences be-
tween the Canadian and the Finnish
surveillance systems. The Canadian
surveillance is conducted through sen-
tinel hospitals, most of which are ter-
tiary-care teaching hospitals (251),
whereas in Finland, all clinical micro-
biology laboratories report MRSA iso-
lations. A national MRSA survey in
Ireland in 1995 revealed a two-week
periodical MRSA prevalence of 12.7
per 100,000 population (123). This
figure is more than five-fold as com-
pared with that of Finland for the
whole year, 2.3 per 100,000 popula-
tion in 1997.
Despite a reasonably good
MRSA situation on the national level
in Finland, numerous strains causing
local intrahospital outbreaks or inter-
hospital epidemics were identified.
New strains emerged throughout the
study period, and twelve strains have
continually been isolated since their
first appearance, although the numbers
of specific strains tend to decline by
time. Genetic alterations, as detected
by PFGE subtype variation, were oc-
casionally observed in strains that re-
appeared after the first outbreak had
been successfully controlled.
Approximately one third of all
MRSA strains in Finland are multisen-
sitive. This is in contrast to elsewhere
in Europe, where only 13 % of MRSA
isolates, collected from 25 university
hospitals in 15 countries through the
SENTRY study, were multisensitive
(76).
6.3 MEC HYPERVARIABLE
REGION
The mec determinants of the 38 epi-
demic and outbreak strains were di-
vided into four different types accord-
ing to their hypervariable region hy-
bridization profiles. An analysis of
sporadic strains from the year 1995
revealed only three additional HVR-
types, each encountered in only one
strain. Previous studies have shown
that hypervariable region analysis by
PCR and sequencing can be used to
distinguish different mec DNA types
(191, 233, 308). Five to eighteen dif-
ferent HVR-types have been identified
in collections of 24-254 strains on the
basis of differences in either the num-
ber or the sequence of dru repeats
(185, 191, 242, 246, 308). Consistently
with the present study, the same HVR-
type was often found in different gen-
otypes. It is also possible that strains
with identical genotypes harbor differ-
ences in HVR types. Five different
subclones were identified among 50
isolates representing one epidemic
strain in Germany (308). In the present
study, the HVR types were mostly
analyzed for one representative of
each strain type, and therefore no con-
clusion can be drawn regarding the
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variety of HVR types within different
strain types.
6.4 MRSA CLONES AND
TRANSMISSIBILITY
Two major groups of MRSA were
identified on the basis of antimicrobi-
al susceptibility testing, ribotyping,
and hybridization analysis of the mec
hypervariable region of 72 epidemic,
local outbreak, and sporadic MRSA
strains. One group contained mainly
sporadic strains showing mec HVR
type A, multisensitivity, and a variety
of ribotypes. The other group con-
tained strains with mec HVR type B
or C in association with two common
ribotypes, and resistance to other an-
tibiotic groups in addition to beta lac-
tams. The latter group contained both
epidemic and sporadic strains. Al-
though two major groups with distinct
genotypic and phenotypic traits were
identified, none of the characteristics
were associated directly with epide-
micity or sporadicity. The failure to
find such an association may be due
to incorrect assignment of sporadic
strains. Any strain isolated from one
person only and showing a unique ph-
age type and/or antimicrobial suscep-
tibility pattern was defined as a spo-
radic strain. A classification of strain
types on the basis of phage typing
alone was later shown to be inade-
quate. In addition, an MLST analysis
of the most common Finnish isolates
from 1997-1999 showed that, although
showing variable PFGE patterns,
many of the previously identified epi-
demic and local outbreak strains ac-
tually descended from a common an-
cestor. Some of the MRSA isolates
originally classified as sporadic may
also have belonged to these clones.
By a combination of several typ-
ing methods (phage typing, ribotyp-
ing, PFGE, and MLST), this study
identified eight clones of MRSA in
Finland. Six of the clones contained
strains showing major MLST se-
quence types recently identified
among MRSA strains from several
different countries (74). Of a total of
twelve international MRSA sequence
types identified in a collection of 359
international MRSA isolates, nine (ST
5, 36, 347, 239, 241, 8, 22, 45, and
30) occurred in ten of the fourteen
Finnish MRSA strains analyzed: Hel-
sinki I, Helsinki V, Turku II, Helsinki
VI, Helsinki VII, Lohja, Kokkola, UK
EMRSA-15, Kemi, and Pori I. In ad-
dition, one strain, Tampere III, was a
single locus variant of ST 247.
Two of the eight MRSA clones
(Joensuu and Mikkeli) encountered in
Finland contained strains showing dif-
ferent molecular epidemiology. Al-
though these two clones were abun-
dant among MRSA strains in Finland,
the MLST sequence type ST 12 of
Joensuu II is commonly found among
international MSSA, but not among
MRSA strains (http://www.mlst.net),
(74), and ST 59, the slv of the Mikke-
li clone has been thus far reported in
one MRSA carrier and in few MSSA
strains (http://www.mlst.net).
Patient-to-patient transmission
of MRSA depends on many factors.
Patients colonized or infected with
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MRSA are the major reservoir in hos-
pitals. Patient risk factors for MRSA
colonization and infection include pre-
vious hospitalization, pressure sores,
indwelling devices, underlying dis-
ease, and recent antibiotic use (47, 64,
236). Other factors promoting the
spread of MRSA include care in high-
risk departments such as burns unit or
intensive care unit (47, 225), staff
shortage (96), frequent patient trans-
fer between wards and hospitals (60,
68), and antibiotic selection (249).
MRSA dissemination may be reduced
by appropriate infection control mea-
sures and antibiotic policies (96).
However, the identification of a rela-
tively small number of global MRSA
clones among the large diversity of S.
aureus clones suggests that strain char-
acteristics also influence the dissemi-
nation of MRSA (http://mlst.net), (51,
54, 74). The majority of the globally
successful clones were also identified
in Finland. Success in transmissibili-
ty seems not to be exclusively due to
SCCmec, since 4 of the 12 recognized
MRSA STs (ST 5, 8, 22, and 45) in
Finland were common among Euro-
pean MSSA strains from the 1990s
(74), (http://www.mlst.net).
The reasons for superior trans-
missibility of some clones still remain
unclear, although several mechanisms
have been suggested. Two epidemic
strains have been shown to possess
better environmental survival than
have three sporadic strains. The recov-
ery capacity of all five strains declined
gradually, but the epidemic strains sur-
vived three months longer, in up to
approximately 1000-fold higher quan-
tities (cfu/ml), than did the sporadic
strains (296). For some strains, en-
hanced transmissibility may result
from better colonization at the expense
of reduced virulence (153), as suggest-
ed for the Canadian epidemic strain
CMRSA-3 (206). CMRSA-3 exhibit-
ed significantly higher fibronecting-
binding and coagulase titers than did
another epidemic strain, CMRSA-1,
and sporadic strains. In the case of
CMRSA-3, the balance towards en-
hanced colonization factor production
may be explained by reduced and de-
layed RNAIII production by the glo-
bal agr regulator (206). CMRSA-1 did
not produce alpha toxin and proteas-
es, and had a limited profile of secret-
ed proteins but a normal level of
RNAIII production. The predominant
subtype of CMRSA-1 expressed a
high molecular weight glycoprotein
known to prevent bacterial adhesion
to fibronecting, fibrinogen, and IgG
(240). However, this protein may con-
fer novel adhesion functions, such as
those related to biofilm formation, and
adherence to cellular lipids (114, 115).
It has also been suggested that a high
number of repeats (≥7) in the polymor-
phic X-region of the protein A gene
would predict an epidemic nature of
MRSA strains. A longer X-region in
epidemic strains may result in a better
exposition of the Fc-binding region of
protein A (81). Another study did not
support this hypothesis, since no cor-
relation was found between the length
of the protein A gene repeats and the
persistence of S. aureus colonization
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(279). In the light of the present and
previous studies and the fact that S.
aureus colonization and virulence re-
sult from a complicated interplay of
numerous factors, it seems that no sin-
gle mechanism is responsible for the
successful transmission of certain
clones. Instead, these clones may har-
bor a wide range of mechanisms af-
fecting transmissibility, and the mech-
anisms may vary between different
clones and even between subtypes of
individual strains (206).
Reliable distinguishing of spo-
radic strains from strains with evident
capacity to spread is crucial in the
search for molecular markers or mech-
anisms for enhanced transmissibility.
This requires representative popula-
tion-based strain collections and care-
ful characterization of isolates. Such
material is available in Finland be-
cause of the national reporting and
typing systems.
6.5 MRSA IN COMMUNITY
Our study showed that, from 1997 to
1999, one fifth of all Finnish MRSA
isolates came from persons who had
had no contact with health-care facil-
ities, suggesting that these MRSA iso-
lates may be community-acquired.
This unexpectedly high proportion of
community-acquired isolates was
identified despite a stringent definition
for community acquisition (22), i.e. a
2-year time period without health-care
facility contact before the MRSA iso-
lation. However, a possibility remains
that some of the MRSA-positive per-
sons may have had health-care facili-
ty contacts before the 2-year cut-off
period, and their MRSA isolates had
been acquired in hospital and had per-
sisted ever since.
Risk factors other than previous
hospital stays were not analyzed in this
study. Further information should be
collected to develop a hypothesis on
risk factors specific for community ac-
quisition. Intravenous drug use, pre-
vious antibiotic use, and underlying
diseases have previously been associ-
ated with community acquisition of
MRSA (147, 176). A recent study cov-
ering 30 months identified a similar
proportion (22%, 20/92) of commu-
nity-acquired MRSA in a university
hospital. Thirteen (65%) persons with
community-acquired MRSA lacked
the known risk factors (27). A known
risk factor was defined as a previous
hospitalization within 12 months, an
underlying chronic disease, the pres-
ence of an indwelling catheter, a his-
tory of surgical procedures, previous
antimicrobial therapy, intravenous
drug use, or a household contact with
an identified MRSA carrier.
Community-acquired MRSA
can be classified into four categories:
1) discharged hospital patients and
hospital staff members with MRSA;
2) nursing-home residents with
MRSA; 3) MRSA transmitted to non-
hospitalized patients; and 4) MRSA
arising de novo in community (48).
Our study focused on the last two cat-
egories by first identifying nonhospi-
talized MRSA-positive persons, and
thereafter comparing their isolates
with those from hospitalized patients
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Of all MRSA strain types isolat-
ed from ten or more persons during
1997-1999, three were associated with
community acquisition: Mikkeli, Joen-
suu, and Helsinki VIII. Coincidental-
ly, all these strain types showed relat-
ed MLST sequence types previously
encountered mostly among successful
MSSA clones, but not among MRSA
clones (74). In addition, three other
strain types were also frequently found
among persons without health-care fa-
cility contacts: Kemi, Kokkola, and
Pori. All these strain types were char-
acterized by multisensitivity and HVR
type A. Preliminary PFGE studies in-
dicate that the strain types similar to
Mikkeli, Joensuu, Kemi, and Pori were
also prevalent among contemporary
MSSA isolates in Finland (unpublished
data). In contrast, the multiresistant
strain types, representing the globally
spread MRSA clones (Brazilian, Ibe-
rian, New York, and the UK EMRSA-
16), were almost exclusively found in
persons who had health-care facility
contacts.
Recent sequencing of a virulent
community-MRSA strain, MW2,
which caused the deaths of four chil-
dren without risk factors (29), suggest-
ed that different factors may be need-
ed for competitive survival in differ-
ent environments (11). Multiresistance
may be biologically costly to maintain,
and provides no additional fitness in
an environment where the antibiotic
selection pressure is low (5). The high-
ly prevalent and virulent community-
MRSA, MW2, grows faster, and has
fewer transposons and insertion se-
quences than have strains adapted to
the hospital environment. In addition,
MW2 harbors virulence factors not
found in other MRSA genomes whose
complete sequences are available
(139). The superantigen enterotoxin
H, the penton-valentine leucocidin, a
bacteriocin, and a collagen-adhesin
were suggested as being partly respon-
sible for the observed virulence (11).
The virulence factors of the identified
community-MRSA strains in Finland
have not yet been assessed in any way.
However, most of the community-ac-
quired MRSA were multisensitive,
and children were more likely to have
a community-acquired than a hospi-
tal-acquired MRSA. These findings
agree with those of previous reports,
suggesting that nonmultiresistant
MRSA is emerging as an important
pathogen in the community (29, 72,
105).
6.6 HORIZONTAL TRANSFER
OF MEC DNA
According to the present study, hori-
zontal transfer of mec DNA has part-
ly influenced the epidemiology of
MRSA in Finland. This is supported
by several findings.
First, we found that similar
MRSA genotypes had different mec
DNA, as assessed by mec hypervari-
able region hybridization and PCR
analysis of the mec-regulatory region.
These results are in line with previous
findings (74, 75, 198) and suggest that
representatives of similar genotypes
may have acquired the mec DNA from
different donors.
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deleted elements. This type of mec
DNA has also been encountered in co-
agulase negative staphylococci (109),
and it may be more capable than other
mec DNAs of confering beta lactam
resistance to community strains of S.
aureus (11, 158). Our results support
this hypothesis.
Emergence of new MRSA
clones has also been encountered in
Germany (305). Furthermore, strains
resistant to fewer antimicrobial groups
than before have also been encoun-
tered in France, and these strains have
progressively replaced previous genet-
ically different, multiresistant MRSA
clones (83, 148, 149).
The mecA gene is widely distrib-
uted among different species of coag-
ulase negative staphylococci (214,
274), and such strains have been de-
tected in both nosocomial infections
and healthy carriers (55, 66). Thus,
donors of mec DNA may be available
both in nosocomial and community
settings.
Overall, it seems evident that the
increase in the number of MRSA is
not exclusively due to clonal dissemi-
nation, but that emergence of de novo
MRSA through horizontal transfer of
mec DNA occurs occasionally.
Second, HVR type A was found
in many different genotypes, most of-
ten in those with a multisensitive an-
timicrobial resistance pattern, but also
in some isolates of Iberian, New York,
and UK EMRSA-16 clones. Other
HVR types were restricted to a few
clones: HVR B in one, C in two, and
D in one clone. These results suggest
that HVR A mec may transfer more
easily than others. It has been suggest-
ed that one mec type (mecSCC IV) can
spread to most, if not all, S. aureus
genotypes (5). The small size of SC-
Cmec IV may explain its enhanced
transfer capacity. Although it remains
to be clarified whether different HVR
types are associated with specific SC-
Cmec types, our data suggest that
HVR type A may be similar to SCC-
mec IV (158, 198)
Third, two common clones of
MRSA in Finland, the Mikkeli and
Joensuu clones, expressed MLST se-
quence types usually found in methi-
cillin-sensitive strains (http://
www.mlst.net). These MRSA clones,
and the Helsinki VIII strain, which is
a triple allele variant of the Joensuu
clone, are multisensitive, express
HVR type A, and are associated with
community acquisition. Furthermore,
methicillin-sensitive S. aureus strains
with PFGE types related to the Mikke-
li and Joensuu clones are common in
Finland. International community-ac-
quired MRSA strains have been
shown to harbor a type of mec DNA,
which lacks resistance determinants
other than the mecA gene, and regions
known to contain mutated or partially
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7. CONCLUSIONS AND CON-
SIDERATIONS FOR THE FU-
TURE
A suitable typing scheme for continu-
ous nationwide MRSA surveillance
was established. In a low prevalence
country, comprehensive molecular
typing, verification of methicillin re-
sistance and S. aureus species, as well
as antimicrobial susceptibility testing
of all new isolates is feasible. Contin-
uous feedback to laboratories and in-
fection control nurses is provided.
MRSA trend in Finland is in-
creasing. However, the incidence of
MRSA is still low as compared with
that in many other European countries
and the USA. The proportion of
MRSA isolated from persons without
hospital contacts was surprisingly
high, one fifth of all isolates.
Two epidemiologically distinct
MRSA populations were found. The
first population consisted of global
MRSA strains, which mainly spread
within and between hospitals through
clonal dissemination. The second pop-
ulation consisted of strains genotypi-
cally related to MSSA. Some of these
strains may emerge through horizon-
tal transfer of mec DNA. Subsequent
clonal dissemination may occur, often
locally in susceptible environments,
such as long-term care facilities. Some
of these strains were associated with
community acquisition.
The two MRSA populations
may require different infection control
measures. The control of global
MRSA in Finland has been quite suc-
cessful, as exemplified by the decline
of such isolates in the largest hospital
district. In contrast, increasing prob-
lems are encountered with the MRSA
population consisting of strains geno-
typically related to MSSA. Although
easier to treat, they may be more dif-
ficult to diagnose because of their low
oxacillin MICs and heteroresistance.
Factors influencing the emergence of
such strains are unknown, but antibi-
otic selection pressure may play a role.
If the emergence of such strains can-
not be hindered, efforts should be
aimed at the prevention of secondary
transmission.
This study brought up several
items which call for more precise re-
search in the future. Further clinical
information should be collected on
persons with community-acquired
MRSA in order to develop a hypothe-
sis on risk factors specific for commu-
nity acquisition. Association of HVR-
types with different SCCmec types
should be addressed. Many open ques-
tions related to the horizontal transfer
of mec DNA remain to be elucidated.
Is HVR type A associated with com-
munity acquisition? Does mec DNA
characterized by HVR type A trans-
fer more easily than do other mec
DNA types? Are the mec-integration
areas different between isolates show-
ing MLST STs common to both
MRSA and MSSA as compared with
those of MSSA exclusively? Further-
more, the SCCmec-types in coagulase
negative staphylococci should be stud-
ied in more detail.
The near future will provide new
techniques for typing and for predict-
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ing the epidemic capacity or pathoge-
nicity of MRSA strains. Both struc-
tural and transcriptional differences in
genomes can be revealed using mi-
croarray hybridizations. PCR or se-
quencing approaches may be devel-
oped for the allotyping of already iden-
tified genomic islands. The availabil-
ity of complete genome sequences of
several strains will result in identifi-
cation of new areas important for the
understanding of the adaptive fitness
of MRSA strains found in different en-
vironments.
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